Identification of deregulated AMPK and mTORC1 signalling in myotonic dystrophy type I and their potential as therapeutic targets by Brockhoff, Marielle
Identification of deregulated AMPK and 
mTORC1 signalling in myotonic dystrophy 
type I and their potential as therapeutic targets 
 
 
 
 
 
 
Inauguraldissertation 
 
zur 
Erlangung der Würde eines Doktors der Philosophie 
vorgelegt der 
Philosophisch-Naturwissenschaftlichen Fakultät 
der Universität Basel 
 
 
von 
 
 
Marielle Brockhoff 
aus Weil der Stadt, Deutschland 
 
 
Basel, Schweiz, 2017 
 
 
 
 
 
 
Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel 
edoc.unibas.ch 
Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät 
 
auf Antrag von: 
 
Prof. Dr. Markus Rüegg 
Prof. Dr. Michael Sinnreich 
Prof. Dr. Christoph Handschin 
 
 
Basel, den. 20.09.2016 
 
 
                                        
 
 
 
          Prof. Dr. Jörg Schibler 
                                      Dekan 


 I 
 
Acknowledgements 
During the last 4 years, with all the ups and downs during my PhD, I was accompanied 
by many nice people who helped me or made me laugh when I needed it. 
First I would like to thank Prof. Michael Sinnreich for giving me the opportunity to 
work on this very interesting project and supporting and motivating me in my work. 
Further I thank Prof. Markus Rüegg, and Prof. Handschin for accepting to be part of my 
committee and for their helpful and critical advice during the committee meetings. I 
would like to thank my colleagues from my group, with whom I have spent so much 
time in the lab: Ruben, Adeline, Jochen, Tatiana, Sabrina, Beat Erne and Lionel.  
In particular, I would like to thank Perrine Castets for everything she has done form me. 
Thank you for taking me on this project, it flipped my (work)-life really upside down. 
You managed to reconstruct my self-confidence that got lost in between and taught me 
so many things, so that I could finally enjoy my work. You always knew how to 
motivate me and I could not imagine to have had a better teacher than you! You were 
always in a good mood and laughing even, when it was getting really, really tough for 
you or me or both of us. Thank you again for everything, I would probably not have 
succeeded without you! Gros Bisous  
PS.: On devrait répéter notre compétition de bras de fer pour voir, si j’ai fait encore 
d’autres progrès sous ta supervision. 
 I also want to thank all my good friends, especially those I met in Basel (Conny, 
Estelle, Lena, Eva,.... don’t be mad at me if I didn’t mention you) with whom I have 
spent so many evenings at the Rhine or other places in Basel talking, laughing, partying. 
Lukas, for being always at my side, making me smile, listening to me, and trying to give 
me advice even when it is not possible. The last tough months of my PhD wouldn’t 
probably have gone that good without you.  
Lastly I would like to thank my parents, who were always supporting me and to whom I 
could always talk to, especially in rough times when life was not always easy to handle. 
I am really grateful for such a funny and crazy family and so happy to have my sister 
and brothers who are always good for doing stupid jokes, playing Mario Kart with me 
or making me laugh. 
 II 
 
  
 III 
 
Abstract 
Myotonic Dystrophy type I (DM1) is a disabling multisystemic disease affecting 
skeletal muscle. The disease is caused by expanded (CTG)n repeats in the 3’UTR of the 
DMPK gene. (CUG)n-RNA-hairpins formed by the elongated transcripts lead to 
sequestration of splicing factors, and thereby to mis-splicing of various genes. Although 
different strategies have been tested to limit splicing defects, no causal treatment is 
available for this debilitating disease. To better understand the pathophysiology 
underlying the disease, we analysed whether DM1-associated muscle alterations may be 
related to a deregulation of central metabolic signalling and/or of the autophagy process 
in muscle. Although muscle atrophy in DM1 has been previously related to altered 
signalling and perturbation in catabolic processes, in-depth investigations into these 
areas are lacking. We showed that muscles from HSALR mice, a well-characterized 
mouse model for DM1, exhibit a defective response to energy restriction. Mutant 
muscles reveal blunted AMPK activation under staved conditions, which might be 
related to splicing-dependent CaMKII deficiency. Additionally, active mTORC1 
signalling is maintained in muscle from starved mutant mice, while Akt is efficiently 
inhibited. We further observed that autophagy flux is impaired in HSALR muscle, which 
may arise from the deregulation of AMPK-mTORC1 signalling; autophagy is even 
more severely affected in human DM1 myotubes. Most importantly, normalization of 
these pathways with pharmacological or dietary approaches improved skeletal muscle 
strength and significantly reduced myotonia in HSALR mice. In particular, the AMPK 
agonist, AICAR, but not metformin, another drug known to induce the AMPK pathway, 
led to a marked amelioration of the relaxation time of mutant muscle, together with 
partial splicing correction of CLCN1. On the other hand, rapamycin, an mTORC1 
inhibitor, and enduring low-protein diet, both reduced myotonia but not DM1-related 
mis-splicing. Furthermore, mTORC1 inhibition increases muscle force in HSALR mice. 
Taken together, this suggests that splicing-dependent as well as alternative, splicing-
independent mechanisms can improve muscle function in DM1. These findings 
highlight the involvement of AMPK-mTORC1 imbalance in the disease and illustrate 
the importance of deregulated cellular processes contributing to DM1 muscle 
pathophysiology. At the same time this opens new avenues regarding therapeutic 
options for DM1, by modulating alternative processes aside from RNA toxicity.  
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Preface 
The neuromuscular disorder Myotonic Dystrophy type I (DM1) is a multisystemic 
disease, which is the most common form of muscular dystrophy in adults. Even though, 
various approaches designed to treat this debilitating disease have been conducted, no 
cure is available to date and current therapies are quite limited in alleviating the 
symptoms associated to DM1. The lack of suitable therapeutic options may be linked to 
the complexity of the pathomechanism of the disease, which is still not fully 
understood. 
The aim of my thesis was to shed light into the complex metabolic signalling 
pathways in DM1 muscle in order to identify novel therapeutic targets. This study 
delineates the discovery of altered cellular and metabolic processes that are involved in 
DM1 muscle pathophysiology, together with the identification of druggable targets. 
Furthermore this works provides different dietary and pharmaceutical approaches and 
discusses the therapeutic potential of the selected targets and treatments. 
The project was conducted in the Neuromuscular Research Group of Prof. 
Michael Sinnreich, Department of Biomedicine, University of Basel under the 
supervision of Dr. Perrine Castets, Biozentrum, University of Basel. The thesis 
comprises a detailed introduction to this work, followed by the manuscript recently 
submitted to the Journal of Clinical Investigation, and lastly a detailed discussion with 
conclusion and outlooks.  
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1. Introduction 
Muscle is the most abundant tissue in the human body, and is subdivided into skeletal, 
smooth and cardiac muscle. Skeletal muscle, a type of striated muscle, represents the 
largest organ in the body accounting for approximately 40% of the human body mass. It 
permits mechanical activity, allowing respiration, body movement and posture 
maintenance, thereby accomplishing essential physiological processes. Importantly, 
skeletal muscle triggers metabolic responses in consequence to contraction and further 
operates as secretory organ communicating with other organs, thus playing an important 
role on the whole body metabolism [1, 2]. 
Consequently, alterations affecting skeletal muscle can lead to various muscle 
diseases. These diseases can be of hereditary or acquired origin, and are embraced by 
the term of neuromuscular disorders (NMDs) [3]. NMDs commonly manifest with 
muscle weakness, sensory disturbances or reflex changes, and display anatomically and 
symptomatically divers patterns. Depending on the type of the disease, patients can 
present muscle pain, cramps, myotonia, severe muscle inflammation to abnormalities in 
the metabolic machinery and many other features that can, as the case may be, mildly 
affect the patients, lead to severe disability or in the worst case to premature death [4]. 
NMDs comprise neuropathies, which affect the peripheral nervous system, diseases of 
the neuromuscular junction (e.g. Myasthenia Gravis or the Eaton-Lambert syndrome), 
and diseases emerging directly from skeletal muscle including myopathies and muscular 
dystrophies [3, 5]. To this day, NMDs are mostly not effectively curable and may still 
be accompanied by major disabilities and life-threatening conditions [5].  
As this work comprises a scientific study about the muscular dystrophy 
Myotonic Dystrophy type 1 (DM1), a summary of skeletal muscle organization and 
function together with selected metabolic processes and signalling pathways in muscle 
is given, followed by a detailed overview and description of DM1 disease and the 
underlying pathomechanism together with the current state of research in this field. 
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1.1   Skeletal muscle organization and function 
 1.1.1 Skeletal muscle architecture: an overview 
Skeletal muscle is attached to the bones by tendons, and is composed of multiple 
bundles, which are ensheathed by connective tissue. Muscle bundles contain numerous 
long cylindrical multinucleated fibres, corresponding to syncytia originating from 
fusion of several myoblasts during myogenesis [6]. Myofibres are composed of aligned 
myofibrils, which consist of repeated units, named sarcomeres, which in turn comprise 
thin and thick filaments. Sarcomeres are the fundamental contractile units of skeletal 
muscle, forming visible bands, which are responsible for the striated appearance of the 
muscle fibres, visible under the microscope. The thin filaments are attached to the Z-
lines, the borders of the sarcomere, and extend to the centre of the sarcomere. Between 
each layer of thin filament, a layer of thick filament is present in the centre of the 
sarcomere. Thick filaments are composed of bundles of myosin, while the thin filaments 
consist of three proteins called actin, tropomyosin and troponin. At rest tropomysin, that 
is controlled by troponin, blocks the myosin-binding sites on the actin molecules. Upon 
liberation of the myosin-binding sites, myosin acts as a motor molecule that interacts 
with the actin filaments, so that the filaments slide past each other in an energy-
dependent fashion, ultimately leading to a shortening of the sarcomere and thereby 
effecting muscle contraction [6, 7]. 
 1.1.2 Force generation and muscle contraction 
Muscle contraction is initiated by single or consecutive action potentials, which are 
transmitted by the innervating motor neurons, through the neuromuscular junctions 
(NMJs) to the muscle fibres. The contraction resulting from one single action potential 
is designated as muscle twitch, while consecutive action potentials trigger a sustained 
muscle contraction termed tetanus. The arriving action potential causes Ca2+ influx 
through voltage-gated calcium channels at the presynaptic site, which triggers the 
release of the neurotransmitter acetylcholine (ACh) at the endings of the motor neuron 
into the synaptic cleft [8, 9]. ACh in turn binds to nicotinic acetylcholine receptors 
(nAChRs) at the sarcolemma of the muscle fibres and triggers the opening of these 
channels, ultimately leading to influx of Na+ and efflux of K+, thus generating a weak 
depolarization of the sarcolemma [8]. In response to the membrane depolarization, 
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voltage sensitive sodium channels NaV1.4 (sodium channel protein skeletal muscle 
subunit alpha) open and allow large quantities of Na+ to enter the muscle fibre, which 
greatly amplifies the depolarization [8]. In this manner an action potential is generated 
and propagates along the membrane of the fibre and into the T-tubules, which are 
invaginations of the sarcolemma [8]. The membrane depolarization induces a 
conformational change of voltage-dependent calcium channels CaV1.1/DHPR (voltage-
gated L-type calcium channel), which further triggers the opening of the RyR1 
(ryanodine receptor 1) calcium channels in the sarcoplasmic reticulum (SR) [6, 8, 10]. 
Ca2+ is released from the SR, binds to troponin and induces interaction of actin and 
myosin filaments, allowing muscle fibre contraction and force generation [6, 7, 11].  
When the action potential ceases, ACh release is discontinued, the remaining 
ACh is reabsorbed into the ending of the motoneuron or is broken down by the 
acetylcholine esterase (AChE) [12]. Further, NaV1.4 channels close, interrupting Na+ 
influx [13]. Repolarization of the membrane is induced by the opening of potassium 
channels, allowing K+ ions to exit the fibre, and is further enforced by the activation of 
the ClC-1 (chloride voltage-gated channel 1) chloride channels, which permit the entry 
of Cl- ions into the cell [13]. Finally, the repolarization leads to inactivation of CaV1.1 
and RyR1 [14]. Ca2+ ions are actively pumped back into the SR via SERCA1 
(sarcoplasmic/endoplasmic reticulum Ca2+ ATPase 1) calcium pumps, thus restoring the 
resting state of the cell [14]. As a consequence of the falling Ca2+ concentration in 
sarcoplasm, Ca2+ dissociates from troponin, the sarcomeres return into their resting 
length, and the muscle relaxes. 
1.2   Processes and signalling pathways at play in muscle 
homeostasis 
Skeletal muscle is a highly dynamic tissue that is exposed to divers physiological 
conditions, including variable nutrient availability, physical exercise or different types 
of hormones like anabolic hormones (e.g. growth hormone, Insulin-like growth factor 1) 
or stress hormones (e.g. glucagon, glucocorticoids) [15-17]. Adequate response and 
adjustments to these stimuli are crucial for maintaining a healthy and balanced cellular 
homeostasis for proper muscle performance. Deregulation of central metabolic 
signalling in muscle can be detrimental and alter muscle function.  
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 1.2.1 Processes involved in proteostasis 
In healthy skeletal muscle tissue, homeostasis relies on well-controlled proteostasis, 
which corresponds to the balance between protein synthesis and protein degradation. 
Rapid and efficient adjustment of required protein synthesis, as well as adequate protein 
breakdown, ensuring protein turnover and removal of toxic products, altered organelles, 
or aggregated proteins are indispensable for muscle function and maintenance of muscle 
mass [15]. Both, excessive or insufficient protein synthesis and inappropriate protein 
degradation in skeletal muscle may be very harmful for muscle tissue but can also 
greatly affect the whole body homeostasis [18]. Therefore, correct regulation of the 
anabolic and catabolic mechanisms is of major importance for muscle and body health. 
The two major processes responsible for proteolysis are the ubiquitin-
proteasome system (UPS) and the autophagy-lysosome system [15]. Generally, the UPS 
selectively targets proteins, while the autophagy flux accounts for the degradation of 
large amounts of proteins and whole organelles [15, 19]. The UPS is implicated in 
controlling the amount of regular proteins and is particularly involved in clearing mis-
folded and damaged proteins [19, 20]. A protein is selectively targeted for degradation 
by conjugation of a polyubiquitin chain, comprising a cascade of enzymatic factors, 
including the ubiquitin-activating enzymes (E1), the ubiquitin-conjugating enzymes 
(E2), and the ubiquitin–protein ligases (E3) [19]. The polyubiquitinated substrate is then 
transferred to the 26S proteasome complex that displays three main catalytic activities: 
the chymotrypsin-like, trypsin-like, and caspase-like activities [20]. The protein is 
degraded by the proteasome into short peptides, which can be recycled and used for 
synthesis of novel proteins [19]. It is known that muscle atrophy can be caused by 
increased activity of the UPS resulting in excessive protein degradation and rapid loss 
of muscle mass [21]. Hence, deregulation of UPS function has been found to be 
implicated in the pathogenesis of different diseases, including NMDs [20, 22, 23]. 
Autophagy is a complex process involving a dynamic flux of autophagic 
vesicles, being necessary for the basal turnover of cytosolic components and the 
removal of aggregated and toxic proteins [24]. Autophagy plays a major role in protein 
catabolism, whereby different stimuli like deprivation of nutrients, energy and 
hormones can elicit autophagy activity. For instance, nutrient restriction is a potent 
trigger of autophagy activity [24, 25]. Upon autophagy induction, double-membraned 
structures called phagophores are formed, further generating vesicles named
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autophagosomes that enclose cytoplasmic proteins and organelles [24, 25]. The 
autophagosome then fuses with lysosomes, and the sequestered material is degraded 
into small peptides, serving as amino acid source for the cell [24, 25]. Detection of LC3 
(MAP1LC3, microtubule-associated protein 1A/1B-light chain 3) has become a reliable 
method for monitoring autophagy flux. At autophagy induction, the cytosolic LC3I is 
lipidated to form LC3II, which is inserted into the autophagosomal membrane [26, 27]. 
At a later stage of autophagy flux, LC3II is degraded [25, 26]. The cargo receptor 
protein p62/SQSTM1 (sequestosome 1) is also an autophagy substrate and constitutes 
another marker commonly used to investigate autophagy; accumulation of p62 can be a 
sign of impaired autophagy [25, 28]. To date, it is known that an immoderate autophagy 
flux, resulting in excessive protein degradation provokes muscle wasting, while 
perseverative decreased autophagy flux triggers the accumulation of altered proteins and 
organelles, which can cause muscle myopathy with myofibre degeneration and muscle 
weakness [15, 21, 29, 30]. Hence, deregulated autophagy process has been found to be 
involved in the pathogenesis of various muscle diseases [30-32].  
 1.2.2 Signalling pathways regulating muscle homeostasis (Scheme 1) 
Skeletal muscle homeostasis and proteostasis are controlled by key metabolic 
signalling, such as the pathways determined by mTORC1 (mammalian target of 
rapamycin complex 1) and AMPK (AMP-activated protein kinase) [33]. These kinases 
sense cellular conditions (i.e. energy and nutrient status) and are regulated by signals 
elicited by growth factors. They respond by switching to the energy and nutrient 
consuming anabolic processes, such as protein synthesis, or to energy and nutrient 
producing catabolic processes, such as protein degradation [33, 34]. 
 Growth factors, including insulin and insulin-like growth factors (IGFs) act via 
the PI3K (phosphoinositide 3-kinase) pathway, in which Akt/PKB (protein kinase B) 
promotes mTORC1 signalling, amongst others, through inhibition of TSC2 (tuberous 
sclerosis complex 2) [35-37]. In parallel amino acids are able to activate mTORC1 via 
the Rag-Ragulator complex [35, 36]. Cell growth and proliferation are promoted by 
mTORC1-dependent induction of protein synthesis via different downstream effectors 
[38].  Activation  of  p70S6K  (p70  ribosomal  S6  kinase) and its downstream target S6   
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Scheme   1:   The   AMPK-­mTORC1   signalling   pathway.   AMPK   and   mTORC1   activities   are   inversely  
related  and   integrate  energy  and  nutrient   (amino  acids)  signals  and  growth   factors   (insulin  and   IGFs)   in  
order   to   determine   if   the   cell   will   switch   to   anabolic   (protein   synthesis)   or   catabolic   (autophagy,   UPS)  
processes.   In   deprived   conditions   AMPK   is   activated,   promoting   autophagy   and   restricting   protein  
synthesis   by   blocking  mTORC1   via  Raptor   and   TSC2.  Ulk1   is   responsible   for   autophagy   induction   and  
regulated  by  AMPK  and  mTORC1.  FoxO  transcription  is  induced  by  AMPK  and  further  promotes  genetic  
expression  of  the  atrogens  (MuRF1  and  Atrogin1)  that  is  required  for  the  activation  of  UPS.  Growth  factors  
act   via   PI3K-­Akt/PKB   pathway,   reducing   FoxO-­dependent   transcription   and   inhibiting   TSC1-­2   complex  
activation.  TSC1-­2   inhibition  and  amino  acids  promote  phosphorylation  of  mTORC1,   thereby  stimulating  
protein  synthesis   through  activation  of  p70S6K-­S6  and   inhibition  of  4EBP1-­eIF4E.  A  negative   feedback  
loop  in  which  mTORC1  inhibits  IRS1  (insulin  receptor  substrate  1)  blunts  PI3K-­Akt/PKB  signalling.  
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(ribosomal protein S6) as well as phosphorylation of 4E-BP1 (Eukaryotic translation 
initiation factor 4E-binding protein 1), preventing its binding to eIF4E, lead to protein 
synthesis by increasing gene transcription and translation [35]. A negative feedback 
loop from mTORC1-p70S6K that inhibits the insulin-IGF pathway further regulates this 
signalling process [39, 40]. On the other hand, mTORC1 is able to inhibit ULK1 (unc-
51 like autophagy activating kinase 1), which leads to reduction of autophagy induction 
[15, 33]. 
Another important component regulated by the Akt/PKB pathway is FoxO 
(forkhead box O) transcription factor. In contrast to mTORC1, FoxO is inhibited by 
Akt/PKB and triggers catabolic signalling. Upon FoxO activation, transcription of 
autophagy-related genes as well as of atrogens, such as the muscle-specific ubiquitin 
ligases TRIM63/MuRF1 (Tripartite Motif Containing 63) and FBXO32/Atrogin1 (F-
Box Protein 32) is induced [41, 42]. Consequently, FoxO triggers protein breakdown 
mediated by the autophagy-lysosome system and the UPS [11, 15, 41].  
AMPK, which is activated upon energy deprivation, is an upstream activator of 
FoxO [11]. Further, AMPK is able to repress mTORC1 signalling through 
phosphorylation of TSC2 and raptor, a specific component of mTORC1 [11, 43]. 
AMPK also induces autophagy by interacting with and phosphorylating ULK1 [15, 33]. 
Hence, mTORC1 and AMPK activities are closely related and consist of the main 
regulators of autophagy and UPS.  
It is well established that transient activation of the Akt-mTORC1 pathway is 
associated with muscle hypertrophy with an increase in the size of myofibres, whereas 
mTORC1 inactivation in skeletal muscle leads to atrophy and muscle degeneration [39, 
44]. Activation of Akt/PKB-mTORC1 pathway can also counteract disuse-induced 
muscle wasting [44]. Inversely, its inhibition with the mTORC1 inhibitor rapamycin or 
by genetically induced repression prevents muscle hypertrophy [44]. However, it has 
also been shown that sustained activation of mTORC1 leads to a late-onset myopathy in 
mice with muscle atrophy and muscle weakness [29, 45]. In parallel, muscle 
hypertrophy has been described in AMPK-deficient mice and increased AMPK activity 
has been related to muscle atrophy [46, 47]. Hence correct and dynamic regulation of 
AMPK and mTORC1 signalling is essential for maintaining muscle homeostasis.  
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 1.2.3 Deregulation of metabolic signalling pathways and NMDs 
A proper balance between anabolic and catabolic processes is essential to maintain 
regular muscle function. Deregulation of Akt-mTORC1 and AMPK pathways, as well 
as abnormal autophagy and proteasomal activity have been related to the pathogenesis 
of different forms of myopathies and dystrophies, including Duchenne muscular 
dystrophy (DMD) or collagen VI-related myopathies [30, 48-50]. Constant activation of 
Akt-mTORC1 pathway in combination with defective autophagy has been observed in 
muscle of patients affected by DMD and mdx mice, a model for this disease [48, 50, 
51]. Similarly, it has been demonstrated that impaired autophagy flux together with 
abnormal Akt and AMPK activity is involved in muscle pathophysiology of collagen 
VI-related myopathies [30]. Importantly myotonic dystrophy type I (DM1) is another 
disease that may be associated to deregulation of metabolic signalling. Indeed, different 
reports suggested that muscle atrophy and weakness in DM1 may be caused by an 
increased catabolic activity and related to abnormal Akt/PKB-mTORC1 signalling [21, 
22, 31, 52, 53]. 
1.3   Myotonic dystrophy type I: from the genetic cause to 
therapeutic strategies 
 1.3.1 Clinical pattern of DM1 
Myotonic dystrophy (Dystrophia myotonica, DM) is a dominantly inherited 
neuromuscular disorder that emerges as two different disease forms named myotonic 
dystrophy type 1 (DM1, Steinert´s disease, OMIM #160900) and myotonic dystrophy 
type 2 (DM2, proximal myotonic myopathy, OMIM #602668). DM1 and DM2 affect 
multiple organ systems, especially compromising skeletal muscle function, and are 
known to be the most common forms of inherited muscular dystrophies in adults [54]. 
DM1 and DM2 share clinical features and pathogenic mechanisms involving abnormal 
polynucleotide repeat expansion mutations. DM1 is more prevalent and generally more 
severe than DM2, and is caused by (CTG)n trinucleotide repeat expansion in the 
3´untranslated region (UTR) of the DMPK (dystrophia myotonica protein kinase) gene 
located at the locus 19q13.3. DM2 is related to a (CCTG)n tetranucleotide expansion in 
the intronic region of the ZNF9 (Zinc finger protein 9) gene located on chromosome 3 
[55, 56]. 
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DM1 presents with a decreased age of onset and increased severity in 
succeeding generations, called genetic anticipation. The severity of the disease roughly 
correlates with the augmentation of the length of the trinucleotide repeat expansion, and 
is increased in consecutive generations [57, 58]. Further the disease is associated with 
various phenotypes, ranging from severely affected new-borns afflicted by life 
threatening complications, to patients with adult onset showing no or only mild 
symptoms [59]. Accordingly DM1 is subdivided into four main clinical forms; 
congenital, childhood-onset, adult-onset and late-onset/asymptomatic, each manifesting 
distinct disease traits, requiring adequate care and therapy [59].  
Myotonia is one of the major characteristics of DM1 being markedly present in 
most of the patients suffering from this disease. The affected individuals present a 
delayed relaxation of skeletal muscle, which can either occur spontaneously or be 
elicited by voluntary contraction or by mild stimulation, such as tapping on a muscle 
(percussion myotonia). Myotonia can manifest already at very early stages of the 
disease, resulting in muscle stiffness and difficulties in relaxing the grip but also 
causing problems when talking, chewing, or swallowing [60, 61]. The cause of 
myotonia in DM1 is generally attributed to reduced Cl- conductance (GCl), due to 
deficiency of the chloride channel ClC-1, resulting in sarcolemmal hyperexcitability; 
the pathological origin of ClC-1 altered function will be discussed in a subsequent 
paragraph. Generally tetanic muscle stimulation is accompanied by extracellular K+ 
accumulation and thus membrane depolarization at the T-tubules due to the shifted K+ 
equilibrium potential (EK) [62]. In healthy muscle ClC-1 is markedly activated after 
repetitive firing of action potentials, generating a Cl- inward flux [62, 63]. Importantly, 
in addition to its small but significant contribution to repolarization of the sarcolemma, 
GCl is of major importance for re-establishing the resting membrane potential [62, 64]. 
As GCl accounts for approximately 80% of the resting membrane conductance (GM), the 
accumulation of K+ and thus the rise of EK is quenched by the presence of the very high 
GCl, as the Cl- equilibrium potential (ECl) stays relatively constant [65]. Additionally, the 
resting membrane potential being stabilized by ECl is more negative than EK, resulting in 
enforced K+ reuptake of the cell [66]. However, in DM1 muscle after tetanic stimulation 
the rise of EK cannot be counteracted due to the important reduction of Cl- flux and is 
sufficient to trigger muscle action potentials without incoming impulses from the 
nervous system [62, 67]. Moreover, K+ ions persist longer in the T-tubule system due 
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the reduced driving force for K+ reuptake. Thereby myotonia manifests after voluntary 
contraction in DM1 patients.  
These spontaneous muscle fibre discharges due to membrane hyperexcitability 
can be monitored by a needle electromyogram (EMG). Insertion of the needle electrode 
into a myotonic muscle triggers consecutive discharges, that may last tens of seconds to 
minutes, whereas healthy muscle will only present a brief electronic signal lasting for a 
few msec [65, 68]. Interestingly, in a recent study the electrophysiological profiles of 
DM1 patients were investigated, by applying an EMG examination protocol that allows 
to distinguish ion-channel deficiencies. The electrophysiological profiles of all DM1 
patients corresponded to chloride channel dysfunction [69]. However, 40% of the 
patients exhibited a certain variation from the typical chloride channel profile [69, 70]. 
It was hypothesized that these deviant profiles may be due to a simultaneous 
dysfunction of ClC-1 and other muscle channels like sodium channels, suggesting that 
the pathogenesis of myotonia in DM1 is more complex than initially suspected [69]. 
Besides myotonia, skeletal muscle alterations in DM1 patients include muscle 
wasting and weakness, which considerably affect the quality of life of the patients. The 
pattern of muscle involvement in DM1 comprises facial- and neck-muscle weakness but 
usually also the distal ends of the limbs, leading to weakness in feet and hands causing 
substantial disability; proximal weakness becomes symptomatic only late in the disease 
course [60]. Moreover, respiratory muscle weakness is common in DM1, eventually 
triggering respiratory failure, which is one of the prevailing causes of death together 
with heart conduction block. Another feature in DM1 is muscle pain that can be 
resistant to treatment, thus severely affecting the well-being of the individuals 
concerned [60]. A variety of gastrointestinal problems like gastroesophageal reflux, 
nausea, vomiting or incontinence rely as well on insufficient functioning of smooth 
muscles and of the muscles of the alimentary tract [60, 71]. Apart from skeletal and 
smooth muscle-related affection, DM1 patients usually show diverse symptoms like 
cataracts, cardiac conduction defects, neurological dysfunctions, endocrine 
abnormalities and metabolic derangements such as insulin resistance [58]. 
Formerly, muscle biopsies were frequently used for DM1 diagnosis, before 
being mostly replaced by genetic testing. Muscle abnormalities characteristic of DM1 
include internalized nuclei, whose number correlates with the muscular involvement of 
the patient [72, 73]. Although centralized nuclei are usually associated to muscle 
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regeneration, the reasons for their accumulation in DM1 is still not fully understood and 
might have other reasons than regeneration [72-75]. Moreover, fibre size variation, 
disordered cytoarchitecture, deranged organization of myofibrils harbouring cellular 
aggregates, abnormal fibre type proportion as well as angulated, ring and atrophic fibres 
are also observed in DM1 muscle [72, 73, 75]. 
 1.3.2 Pathogenic cause of DM1 (Scheme 2)  
As aforementioned DM1 is caused by (CTG)n trinucleotide repeat expansion in the 
3´untranslated region (UTR) of the DMPK gene. Currently, the commonly accepted 
hypothesis relates the primary cause of DM1 pathogenesis to a toxic gain-of-function of 
the expanded (CUG)n-RNA that is generated upon transcription of the genomic (CTG)n 
abnormal repeats [76].  
Contribution of DM1 mouse models to the understanding of DM1 pathomechanism 
Mutant DMPK transcripts are retained as foci within nuclei, which leads to reduced 
DMPK protein levels [77]. Initially, the reduced DMPK levels suggested a role for 
DMPK haploinsufficiency in the pathology. However, Dmpk knockout mice   (Dmpk-/-) 
that were generated to investigate this hypothesis, only exhibited a very mild phenotype 
and failed to reproduce the multisystemic DM1 pathology [78, 79]. Still, these mice 
exhibited a late onset progressive skeletal myopathy, some cardiac conduction 
abnormalities and altered calcium homeostasis, suggesting that DMPK deficiency may 
contribute in part to DM1 pathogenesis [78-81]. 
Later on, the transgenic HSALR mouse model, that expresses approximately 250 
CTG repeats in the 3’UTR of the human skeletal actin gene (HSA), demonstrated the 
crucial role of toxic expanded RNA transcripts in DM1 muscle-pathology [82]. These 
mice reproduce the genetic pathological origin specifically in muscles and exhibit an 
distinctive phenotype, showing myopathy that aggravates during ageing. It has been 
established that this lineage reiterates the main features of the muscle pathophysiology 
described in DM1 patients, including myotonic discharges, and similar muscle histology 
with multiple central nuclei and variability of fibre size [82, 83]. This model also 
displays specific molecular characteristics described in patients such as MBNL1 
sequestration by the (CUG)n-hairpins into nuclear foci, leading to reduced availability 
of MBLN1 [84, 85]. Analysis of the Mbnl1 knockout mouse (Mbnl1ΔE3/ΔE3), another 
DM1 mouse model, has been of major importance to understand that MBNL1 reduction   
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Scheme   2:   Pathomechanism   of   DM1.   A)   The   molecular   mechanism   of   DM1   relies   on   a   mutated  
(CTG)n   repeat   expansion   in   the   3’UTR   of   the  DMPK   gene.   In   healthy   individuals   the   (CTG)n   repeat  
fragment   varies   between   5   to   37   repeats.   The   severity   of   the   disease   correlates   with   the   size   of   the  
repeat   expansion   and  aggravates  with   the  ascending   amount   of   repeats.   B)  Upon   transcription   of   the  
mutated  DMPK   gene   a   toxic   gain-­of-­function  mRNA   is   generated   that   forms   double-­stranded   hairpin  
structures,   leading  to  reduced  DMPK  protein  levels.  C)  The  toxic  transcripts  disturb   the  distribution  and  
function  of  several  RNA-­binding  proteins,  leading  to  sequestration  of  the  splicing  factor  MBNL1,  leaching  
of   different   transcription   factors   (TFs)   and   stabilization   of  CUG-­BP1.  D)   These   processes   trigger   pre-­
mRNA  mis-­splicing,  affect  mRNA  transport  and  stability,  alter  transcription  and  translation  and  influence  
miRNA  regulation,  which  results  ultimately  in  multiple  disease  symptoms.  
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is crucial for the pathogenesis of DM1. Depletion of MBNL1 in skeletal muscle leads to 
symptoms characteristic of DM1, like myotonia, altered muscle histology, cataracts as 
well as behavioural problems (e.g. increased anxiety or decreased motivation) [86, 87].  
To date it is known that normal tissue development goes along with an enrichment of 
MBNL1 protein in the nucleoplasm. By contrast, in DM1 cells as well in HSALR mice 
the protein is sequestered by the (CUG)n-hairpins, leading to decreased MBNL1 levels 
[85]. MBNL1 has been reported to be a splicing factor that is crucial in regulating the 
transition from the neonatal to the adult splicing-program of its targets [85, 88]. 
Consequently, the reduction of MBNL1 leads to an abnormal adult-to-neonatal splicing-
switch of various pre-RNAs, including CLCN1 (muscle specific chloride channel 1) and 
ATP2A1/SERCA1 (ATPase Sarcoplasmic/Endoplasmic Reticulum Ca2+ Transporting 
1), in DM1 muscle as well as in Mbnl1ΔE3/ΔE3 and HSALR mice [84-86]. Different studies 
have demonstrated a direct link between the development of myotonia and the 
persistence of neonatal ClC-1 isoform in muscle tissue of both mouse models, hence 
emphasizing the importance of expanded transcripts and MBNL1 sequestration in the 
development of DM1 pathogenesis [84-86]. 
Spliceopathy as a pathomechanism for DM1 
Mis-splicing of several pre-mRNAs is thought to result in the multiple disease 
symptoms of DM1 (Scheme 2) [54, 89]. MBNL1 is not the only RNA-binding protein 
that is affected by the generation of toxic gain-of-function RNA. The mutant transcripts 
disturb the distribution and function of several RNA-binding proteins, amongst other of 
the splicing regulator CUG-BP1 (CUG binding protein 1), which has an antagonistic 
function to MBNL1 [90, 91]. Indeed, the elongated transcripts promote the activation of 
the PKC (protein kinase C) pathway, which in turn triggers phosphorylation and thus 
stabilization of CUG-BP1 [92]. In contrast to MBNL1, the steady-state levels of CUG-
BP1 are increased in DM1 tissue, whereas a decrease is observed in healthy individuals 
upon embryonic-to-adult transition [90, 91].  
Consequently, MBNL1 and CUG-BP1, which are both key splicing regulators, 
are suggested to strongly contribute to DM1 pathogenesis by triggering an inappropriate 
shift from postnatal to embryonic splicing patterns of more than 30 genes [85, 86, 93, 
94]. CLCN1, ATP2A1, INSR (insulin receptor) and TNNT2 (cardiac troponin T), all 
being mis-spliced in DM1 context, are well-known targets of one or both splicing 
factors [84, 93, 95-98]. Aberrant splicing of the TNNT2 gene is associated with the 
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cardiac conduction defects detected in DM1 patients, while increased exon 11 skipping 
in the INSR pre-mRNA is responsible for the altered expression and signalling capacity 
of the insulin receptor (IR), and thereby for the insulin resistance observed in DM1 
patients [89, 91, 95]. Myotonia has been related to mis-regulated splicing of the CLCN1 
gene, combining an inclusion of the exons 6B and/or 7A, and retention of intron 2, 
which induces a frameshift in CLCN1 transcripts, generating premature termination 
codons [84, 99, 100]. Nonsense-mediated mRNA decay is responsible for the 
degradation of the expressed transcripts, while the spared transcripts produce a 
truncated protein, leading ultimately to decreased ClC-1 protein levels [99-101]. This 
gives rise to reduced resting chloride conductance contributing to myotonic discharges 
[99-101]. 
Other mis-splicing events affecting genes involved in muscle calcium-handling, 
like RyR1 (ryanodine receptor 1) and CACNA1S (voltage-gated calcium channel 
subunit alpha Cav1.1) were linked to deregulated calcium homeostasis and excitation-
contraction coupling, which may eventually participate in the pathological process 
leading to muscle weakness and atrophy and contribute to sarcolemmal 
hyperexcitability [102-104]. In particular, a recent report demonstrated functional 
differences between the adult (1a) and neonatal (1b) isoforms of SERCA1 protein, 
involved in intracellular calcium homeostasis in muscle. Therefore, increased 
expression of SERCA1b in the DM1 context may be part of the pathomechanism 
causing myotonia and other symptoms [105]. 
DM1, not only a spliceopathy? 
Obviously, splicing alterations play a major role in the pathomechanism leading to 
DM1. Nevertheless, growing evidence suggests that mRNA toxicity has a broader 
spectrum of implications beyond mis-splicing and indicates that the molecular 
pathomechanism is more complex than previously expected [75, 106, 107].  
Apart from their well-known function as splicing factors, MBNL1 and CUG-
BP1 might affect mRNA transport and stability and may therefore have an impact on 
transcription, translation and thus on various cell signalling pathways [94, 106, 108]. It 
is suggested that reduced MBNL1 levels impact on the processing of certain miRNAs 
that are deregulated in DM1 heart and skeletal muscle tissue, hence contributing to 
disease pathology [109, 110]. Furthermore, a process known as RNA leaching 
corresponding to the interaction of transcription factors (TFs) with the expanded 
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(CUG)n-RNA occurs in DM1 cells [111]. Leaching of TFs supposedly relies on their 
ability to bind double-stranded DNA and double-stranded RNA, whereby the TFs are 
removed from the chromatin and displaced from their site of action [111]. In 
consequence, the leached TFs exhibit an abnormal activity, resulting in altered 
transcription of their target genes in DM1 tissue [111]. A well-known example is the 
modification of the levels of the myogenic factor MyoD, which contributes to the 
reduced differentiation and regeneration capacities of DM1 muscle cells [112].  
Another process, independent of mis-splicing, has more recently been suggested 
to contribute to DM1 and corresponds to a cis-effect. The (CTG)n repeat expansion is 
supposed to alter the structure of the chromatin, thus influencing the expression of the 
DMPK gene itself and that of the adjacent genes [113, 114]. As mentioned before, 
DMPK deficiency may partially contribute to DM1 muscle pathology [78-81]. 
Moreover, in different mouse models the deletion of the Six5 (Sine Oculis Homeobox 
Homolog 5) gene, which is situated next to DMPK in human, generated premature 
cataracts, cardiac conduction defects and testicular atrophy [115-118]. DMWD 
(dystrophia myotonica-containing WD repeat motif), another gene adjacent to DMPK 
was also shown to be decreased in human DM1 cells, substantiating the hypothesis that 
(CTG)n repeat expansion induces chromatin condensation and alters gene expression in 
DM1 context, thereby contributing to disease pathogenesis [114]. 
 1.3.3 Pathomechanisms leading to muscle alterations in DM1 
Despite the established hypothesis relating the primary cause of DM1 pathogenesis to a 
toxic gain-of-function RNA, the downstream processes by which muscle weakness, 
atrophy and histological alterations arise are still not well understood. 
Altered cellular processes that may contribute to muscle atrophy 
As mentioned before, correct functioning of autophagy is crucial for healthy muscle 
homeostasis and its deregulation can lead to muscle wasting and cell death. In 
myoblasts from DM1 patients, increased autophagy has been suggested, based on the 
presence of autophagic vacuoles and elevated expression of autophagy markers [52, 53]. 
Another recent report has related muscle atrophy in a DM1 Drosophila model to an 
increased autophagic flux [31]. At the same time it was shown that inhibition of 
autophagy had a beneficial effect on the muscle pathophysiology in the mutant flies, 
hence indicating that autophagy might play an important role in DM1 muscle pathology 
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[31]. Of note, down-regulation of the genes AKT1S1/PRAS40 (AKT1 Substrate 1) and 
AKT2 (V-Akt Murine Thymoma Viral Oncogene Homolog 2) negatively regulating 
autophagy could as well be detected in DM1 patient biopsies [31].  
Another catabolic pathway being potentially altered in DM1 is the UPS. 
Increased activation of the UPS has been reported in a DM1 mouse model (DM300-
328), suggesting a possible contribution to muscle wasting in these mice, and eventually 
being associated to muscle loss in DM1 patients [21, 22]. In addition, muscle wasting 
and weakness in DM1 has been linked to increased apoptosis, as human DM1 myotubes 
were shown to exhibit increased apoptotic activity [31, 52, 53, 119]. These results are 
consistent with the data obtained in the forecited DM1 Drosophila model, 
demonstrating that increased apoptosis goes along with decreased muscle area [31, 52, 
53, 119]. 
To date, it is supposed that the process of myogenesis, which is responsible for 
generation and regeneration of muscle tissue, is impaired in DM1 disease [120]. For 
muscle regeneration, correct activation of myogenic progenitor cells, known as satellite 
cells, followed by proliferation of myoblasts and subsequent differentiation to 
myofibres is required [120]. Presumably, reduced regenerative capacities exhibited in 
DM1 muscle contribute to the muscle pathology in DM1 [53, 83, 121]. It has been 
speculated that reduced satellite cell activation, altered differentiation or a combination 
of these defects, contribute to impaired muscle regeneration and entail muscle weakness 
and atrophy in DM1 [52, 83, 122-124]. 
Perturbation of signalling pathways that may be involved in muscle alterations 
Tweak-Fn14 (tumor necrosis factor-like weak inducer of apoptosis - fibroblast growth 
factor-inducible 14) signalling, being implicated in different processes including 
regeneration, autophagy and metabolism, proved to be of major importance concerning 
muscle pathology in an inducible DM1 mouse model (DM5), which overexpresses an 
eGFP-DMPK 3ʹ′ UTR (CUG)5 mRNA [124, 125]. In fact, Fn14 was found to be 
induced in DM5 mice but also in tissue from DM1 patients [124]. Blockage of Tweak-
Fn14 signalling in mutant mice improved the deficient satellite cell response, as well as 
muscle histology and function, thereby pointing out its potential involvement in DM1 
pathogenesis [124].  
GSK3β (glycogen synthase kinase 3β) is another component being upregulated 
in DM1 context and has additionally been shown to be mis-regulated during 
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myogenesis in human DM1 cells [83]. Pharmacological treatment normalizing GSK3β 
levels in HSALR mice ameliorated satellite cell activation, muscle force, histology and 
decreased myotonia in the mutant mice [83]. 
Interestingly, the insulin receptor (IR), being altered in DM1, is upstream of the 
Akt/PKB pathway, which is involved in cell survival, growth and proliferation 
signalling. As quoted-above Akt/PKB is also a determinant coordinator of cell 
metabolism by regulating protein synthesis, autophagy and the UPS [126]. Akt/PKB 
was found to be inhibited in the heart of Dmpk-/- mice, but no data are available for the 
Akt/PKB status in skeletal muscle of these mice [127]. By contrast, one report 
suggested that human DM1 muscle biopsies show increased Akt/PKB levels, while the 
activation state of the Akt/PKB pathway in primary DM1 myoblasts is unclear [53, 
128]. Hence, whether Akt/PKB deregulation could play a role in DM1 muscle 
pathophysiology is unknown. However, different reports identified a decreased 
activation of mTORC1, a downstream target of Akt/PKB [31, 52, 129]. One study 
relates abnormal activation of p53 to mTORC1 down-regulation and increased 
autophagy activation in human DM1 myoblasts [52]. The potential implication of 
mTORC1 deregulation in DM1 muscle pathology has further been emphasized in the 
DM1 Drosophila model. Overexpression of mTORC1 reduced autophagy and apoptosis 
and rescued muscle mass formation in the DM1 flies [31]. Overall this indicates that 
deregulated signalling pathways might play an important role in DM1 pathogenesis. 
 1.3.4 Current treatments and novel therapeutic strategies 
At present, no treatment is available, which may halt the course of this debilitating 
disease. Patients are closely monitored and usually different treatments are combined in 
order to resolve or alleviate the symptoms. Diabetes is medicated by insulin or oral 
drugs like metformin, while methylphenidate is used occasionally to treat daytime 
sleepiness [58]. Severe health conditions might deserve surgical intervention, including 
pacemaker implantation, removal of cataracts or correction of major spine deformation 
in order to mitigate respiratory impairment [130]. Patients suffering from pain may 
benefit from anti-inflammatories or anti-myotonia therapy. Mexiletine has been reported 
to effectively improve myotonia in DM1. This drug does not seem to affect ClC-1 
function, but reduction in myotonia probably results from nonspecific blockade of 
sodium channels [131, 132]. Further sodium channel blockers like tocainide, 
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procainamide and others, as well as calcium channel blockers such as nifedipine have 
also been reported to reduce myotonia and represent potential treatments for DM1 
patients [131, 132]. However, the available therapeutic approaches remain insufficient, 
especially for the severe cases of DM1, hence pointing to the urgent necessity of 
exploring alternative, novel treatments for the disease. 
With the progressing knowledge on the pathomechanism underlying DM1, new 
options have emerged for DM1-specific therapeutic strategies. Since the formation of 
toxic gain-of-function mRNA is central in DM1 pathology, targeting the elongated 
transcripts seems to be the most promising approach. This can be achieved in two 
different ways: either by liberating the RNA-binding proteins, making their binding 
sites unavailable, or by targeting the elongated transcripts for degradation. Two reports 
demonstrated efficient displacement of CUG-binding proteins from mRNA hairpins, 
using ASOs (antisense oligonucleotides) [133, 134]. ASOs were also applied in in vivo 
approaches, mediating degradation of the toxic RNA by the RNase H [135, 136]. These 
oligonucleotides either targeted directly the CUG repeat or alternatively targeted the 5’- 
or 3’-UTRs of the toxic transcripts in different DM1 mouse models [135, 136]. A major 
reduction of CUG-repeat transcript levels and nuclear foci was observed, as well as a 
partial improvement of splicing and myotonia [137]. Another auspicious study 
employed synthetic small interference RNA (siRNA) in order to target the expanded 
RNA in HSALR mice, leading to an almost complete abolition of mis-splicing and 
myotonia [137].  
Based on the principle that MBNL1 displacement from the toxic RNA is 
sufficient to curtail DM1 disease, a vast range of potent small molecules has been tested 
and identified in DM1 cells and mouse models [133, 138]. At the moment small 
molecules represent another very attractive therapeutic alternative, showing a good 
efficacy, being cheap in production and simple to administrate. More screenings for hit 
compounds with suitable selectivity and low toxicity are ongoing, as well as 
investigations on structure and molecular composition of lead compounds in order to 
improve the efficacy of such strategies [138]. 
In a recent publication from Laustriat et al. (2015), metformin has been 
suggested as potential therapeutic treatment, irrespective of its anti-diabetic application 
[139]. Metformin has been shown to revert or alleviate altered splicing in vitro, such as 
ATP2A1 mis-splicing in DM1 myoblasts or CLCN1 mis-splicing in human DM1 MPCs 
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(mesodermal precursor cells) transfected with a CLCN1 minigene [139]. It is suggested 
that the mechanism triggering splicing corrections involves metformin-induced AMPK 
activation and inhibition of RBM3 (RNA Binding Motif Protein 3) gene expression 
[139]. This hypothesis is supported by the fact that another AMPK activator, named 
AICAR (5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside) was as well able to 
decrease RBM3 expression and to restore mis-splicing of several gene transcripts in 
human DM1 myoblasts [139]. Another study (PCT publication no.: WO 2011121109 
A1) did also suggest AMPK activators, like metformin or troglitazone, as potential 
therapy option in DM1 patients. Though, the correction of mis-splicing of INSR, 
ATP2A1 and TNNT2 transcripts due to AMPK activation has been linked to the 
modulation of the RNA-binding protein ELAVL1/HuR (ELAV-like protein 1) that 
exerts an opposed action to MBNL1, when situated in the cytoplasm. AMPK activators 
were shown to positively stimulate importin activity, which enhances ELAVL1 nuclear 
import and thus depletes the cytoplasmic levels of the protein. However, ELAVL1 does 
not co-localize and thereby act on foci level. Thus the positive effect upon treatment is 
rather linked to decreased cytoplasmic levels of ELAVL1, but the exact mechanism 
counteracting mis-splicing in DM1 cells due to ELAVL1 modulation remains unknown. 
Together these studies provide quite promising results, although there are still 
unsolved issues, like delivery problems, toxicity and insufficient efficiency. Moreover, 
the complex pathophysiology associated with DM1 most likely requires targeting of 
multiple components, as single-agent or single-target therapeutic approaches are often 
limited in their efficacy [140]. While clinical trials are currently ongoing for better 
symptom management, broader investigations are required to further understand the 
mechanisms underlying DM1-associated muscle defects and identify solutions to 
circumvent functional muscle alterations.   
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2. Research aims and questions raised during the study  
To date, most studies investigating the pathomechanism of DM1 have focused on the 
consequences of splicing defects generated by the toxic gain-of-function RNA. Hence, 
development of therapeutic strategies in order to abolish splicing abnormalities in DM1 
context has been of major interest. In the last years, evidence emerged that the 
pathogenic cause of this disease is more complex than previously expected and that 
splicing-independent mechanisms or altered signalling processes that might be 
secondary to mis-splicing may considerably contribute to the multisystemic symptoms 
observed in DM1 patients. Thus, exploring the molecular mechanisms affecting skeletal 
muscle is crucial to understand the onset and progression of the DM1 disease, to be able 
to identify alternative therapeutic targets and to develop novel therapeutic approaches 
for this devastating disease. 
In this study we focussed on the consequences triggered by the perturbation of 
certain metabolic pathways and processes. More specifically, we investigated the 
involvement of abnormal AMPK and Akt/PKB-mTORC1 signalling, as well as 
autophagy impairment in DM1 muscle pathology. Different studies reported a decreased 
activation of mTORC1 in DM1 context, that could eventually be responsible for the 
increased autophagic flux described in some DM1 cell lines [31, 52, 129]. Additionally, 
a potential deregulation of Akt/PKB was proposed, but the results remain contradictory 
regarding the status of the signalling in DM1 tissues and cells [53, 127, 128]. 
Considering that Akt/PKB-mTORC1 and AMPK signalling is central in regulating 
skeletal muscle homeostasis, examination of the state of these pathways is of major 
interest. Furthermore, it is paramount to clarify how or if the deregulation of Akt/PKB-
mTORC1 and AMPK impacts on autophagy and if they contribute to muscle 
dysfunction in DM1 pathology. Moreover a recent report suggested that AMPK 
activation might be beneficial in DM1 cells, although the status of the signalling in the 
DM1 context was not investigated. Normalization of mTORC1, GSK3β, Fn14 and/or of 
abnormal autophagic flux, has recently been shown to be able to improve muscle 
pathophysiology in various neuromuscular diseases, including DM1, which opened new 
perspectives in terms of treatments [30, 31, 51, 83, 124]. For this reason, we addressed 
the question whether, pharmacological or dietary approaches would be suitable to 
normalize the identified deregulated processes, and be further able to resolve or improve 
splicing defects and muscle pathophysiology in DM1.  
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3. Results 
3.1 Manuscript 
The following manuscript refers to the version that was submitted to the Journal of 
Clinical Investigation in July 2016. 
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Abstract 
Myotonic Dystrophy type I (DM1) is a disabling multisystemic disease affecting 
predominantly skeletal muscle. It is caused by expanded CTG repeats in the 3’UTR of 
the DMPK gene. RNA-hairpins formed by the elongated transcripts sequester RNA-
binding proteins leading to mis-splicing of numerous pre-mRNAs. Here, we 
investigated whether DM1-associated muscle pathology may be related to a 
deregulation of central metabolic pathways, which may constitute novel therapeutic 
targets for the disease. We showed that activation of AMPK signaling is impaired under 
starved conditions in muscle from HSALR mice, a well-characterized mouse model for 
DM1, while mTORC1 remains active. As a consequence, autophagic flux was perturbed 
in HSALR muscle, as well as in cultured human DM1 myotubes. Pharmacological 
approaches targeting AMPK/mTORC1 signaling greatly ameliorated muscle function in 
DM1. AMPK activation by AICAR led to a strong reduction of myotonia, accompanied 
by partial correction of mis-regulated alternative splicing. Rapamycin, an mTORC1 
inhibitor, improved muscle relaxation and increased muscle force in HSALR mice 
without affecting splicing. These findings highlight the involvement of 
AMPK/mTORC1 deregulation in DM1 muscle pathophysiology and may open new 
avenues for the treatment of the disease.  
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Introduction 
Myotonic Dystrophy type I (DM1, #160900) is a multisystemic neuromuscular disorder, 
which represents the most common form of muscular dystrophy in adults [141]. In 
particular, DM1 patients suffer from muscle wasting, weakness, and myotonia. DM1 is 
an autosomal dominant disease caused by an expansion of unstable CTG repeats located 
within the 3’ untranslated region of the dystrophia myotonica protein kinase (DMPK) 
gene. Toxic expanded transcripts containing RNA-hairpins formed by the triplet repeats 
accumulate as RNA foci in the nuclei of affected cells [142, 143]. These mutant 
transcripts are thought to sequester RNA-binding proteins, such as muscleblind-like 1 
(MBNL1) and to increase CUG triplet repeat RNA-Binding Protein 1 (CUGBP1) levels. 
The resulting splicing defects are considered the primary cause of DM1 symptoms [82, 
91, 144]. HSALR mice, which carry a CTG repeat expansion in the human skeletal actin 
(HSA) gene, constitute a well-characterized mouse model for DM1 [82]. These mice 
express (CUG)n-expanded transcripts specifically in skeletal muscle and reiterate the 
dystrophic phenotype and myotonic discharges observed in muscle of patients. HSALR 
mice also recapitulate DM1 molecular characteristics such as foci accumulation, 
MBNL1 sequestration, and splicing abnormalities [82, 145, 146]. Therapeutic strategies 
have mainly focused on targeting DM1-associated mis-splicing and mRNA toxicity 
[133, 147, 148], although a more complete understanding of pathogenic pathways 
would clearly be of interest for the development of alternative or additional therapeutic 
options. 
Recently, deregulation of cellular processes and signaling pathways important 
for maintaining proper muscle homeostasis, has been reported in DM1. This includes 
abnormal activation of the ubiquitin-proteasome system and increased autophagic flux, 
which were both related to muscle atrophy and weakness in DM1 [149-151]. In parallel, 
perturbation in the PKB/Akt pathway may arise from altered expression of the insulin 
receptor, which correlates with glucose intolerance in DM1 patients [152]. Although 
PKB/Akt deregulation has been reported in Dmpk-deficient mice [127], in DM1 flies 
[150] and in DM1 human neural stem cells [153], contradictory results have been 
obtained in human muscle cells [128, 154].  
To obtain further insight into the pathomechanisms associated with the disease, 
we investigated whether deregulated metabolic pathways may be involved in muscle 
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alterations in DM1. We uncovered that muscles from HSALR mice do not efficiently 
respond to fasting by displaying impaired activation of AMPK and delayed inhibition of 
the mTORC1 (mTOR complex 1) pathway. Moreover, we observed impaired 
autophagic flux in both HSALR muscle and myotubes from DM1 patients, which may 
arise from AMPK/mTORC1 deregulation. Importantly, we established that treatments 
normalizing these pathways improved skeletal muscle strength and strongly reduced the 
myotonia in HSALR mice. Our data provide evidence for the pathological role of 
metabolic pathways in DM1 and may open interesting avenues for alternative 
therapeutic strategies for the disease. 
Results  
AMPK and mTORC1 pathways are deregulated in HSALR muscle. To identify 
pathomechanisms involved in DM1-related muscle alterations, we examined the 
potential deregulation of metabolic pathways in HSALR mice (Supplemental Figure 1A). 
To this purpose, the activation state of key proteins was compared in muscle from 2-
month-old mice analyzed in fed conditions or submitted to a physiological stimulus like 
fasting [155]. No major difference was observed in the activation state of AMPK, 
PKB/Akt and mTORC1 pathways in muscle from fed mutant and control mice, as 
reflected by the similar phosphorylation levels of AMPK (AMPKP172), PKB/Akt 
(AktP473) and mTORC1 targets, ribosomal protein S6 kinase (p70S6KP389) and S6 
ribosomal protein (S6P235/6) (Figure 1, A and B). After 24 h of starvation, HSALR mice 
showed impaired activation of the AMPK pathway, as revealed by the reduced levels of 
AMPKP172 in tibialis anterior (TA) mutant muscle (Figure 1A). Regardless of the 
nutritional status, protein expression of the known AMPK regulatory kinases, liver 
kinase B1 (LKB1) and transforming growth factor beta-activated kinase 1 (TAK1) was 
unchanged in HSALR muscle compared to control (Figure 1A). In contrast, mutant 
muscle displayed an altered expression profile for Ca2+-calmodulin dependent kinase II 
(CaMKII) isoforms, with marked reduction in levels of the CaMKIIβM muscle-specific 
form and of its phosphorylated, active form (Figure 1A). Such deregulation was 
consistent with splicing defects in the Camk2 genes previously described in tissues from 
DM1 patients and mouse models [148, 156-158]. We confirmed by quantitative PCR 
that splicing of Camk2b was altered in muscle from HSALR mice (exon 13 exclusion), 
while overall expression of Camk2 transcripts was unchanged compared to controls 
(Supplemental  Figure  1,  B  and  C).  As  CaMKII  regulates  AMPK  [159-161],  these  
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Figure  1:  AMPK  and  mTORC1  pathways  do  not  respond  to  starvation  in  HSALR  muscle.  (A,  B)  Two-­
month-­old  HSALR   and   control   (Ctrl)   mice   were   examined   in   fed   conditions   and   after   24   h   of   starvation  
(St24).  Immunoblots  for  phospho-­  (P)  and  total  proteins  of  the  AMPK  (A,  n=3-­4  per  group)  and  mTORC1  
(B,  n=3-­7)  pathways   reveal   reduced  AMPK  activation  and   increased  phosphorylation  of   some  mTORC1  
targets   upon   starvation   in   mutant   muscle.   (C)   Immunostaining   on   muscle   cross-­sections   from   fed   and  
starved   (St24)  HSALR   and   control   (Ctrl)   mice   shows   high   levels   of   phospho-­S6   in  mutant  muscle   upon  
starvation.   Scale   bar,   100   µm.   (D   -­   F)   Immunoblots   for   phospho-­   (P)   and   total   AMPK   and   S6   proteins  
reveal   efficient   inhibition   of   mTORC1   signaling   upon   45   h   of   starvation   (St45)   (D,   n=3-­4)   and   with  
metformin   (E,   n=3-­4)   or   rapamycin   (F,   n=3-­4)   treatment   in   muscle   from  HSALR   mice.   AMPK   activation  
shows  a  trend  towards  increase  in  mutant  muscle  with  metformin  treatment  (E).  Data  are  relative  to  control  
fed   (A,  B,  D)  or  vehicle-­treated   (E,  F)  mice  and  are  mean  ±  SEM.  *p<0.05,   **p<0.01,   ***p<0.001,  2-­way  
ANOVA  with  Tukey’s  multiple  comparisons  test  correction.  
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results suggest that impaired AMPK activation in HSALR muscle may rely on mis-
splicing-dependent CaMKII deficiency. 
In parallel, higher phosphorylation of p70S6K and S6 was detected upon 
starvation in HSALR muscle compared to control muscle (Figure 1B). Accumulation of 
phosphorylated S6 in muscle from starved mutant mice was further confirmed by 
immunostaining (Figure 1C), suggesting an abnormal activation of the mTORC1 
signaling in HSALR mice. Of note, no major change in the phosphorylation of mTOR 
was observed in mutant and control muscles from fed vs. starved mice (Figure 1B). 
Moreover, upon starvation, changes in 4E-BP1 levels were similar between HSALR and 
control muscles (Figure 1B), consistent with previous reports indicating differential 
regulation of mTORC1 targets [162]. Interestingly, mTORC1 deregulation was not 
related to abnormal activity of PKB/Akt since levels of the active phosphorylated form 
of PKB/Akt were efficiently decreased upon starvation in mutant mice (Figure 1B). 
Accordingly, we did not detect any changes in the splicing (exon 11, mis-spliced in 
DM1 patients) or expression of the gene encoding insulin receptor (Insr) in TA muscle 
from 2-month-old HSALR mice (Supplemental Figure 1D). Moreover, mTORC1 and 
AMPK activation state in non-muscle tissue, such as liver, was similar in control and 
mutant mice (Supplemental Figure 1E), indicating that deregulation of these pathways 
is confined to skeletal muscles, which specifically express (CUG)n-expanded 
transcripts.  
 In an attempt to normalize mTORC1/AMPK pathways, control and HSALR mice 
were subjected to starvation for 45 h. Mutant mice lost less weight than control mice 
after prolonged starvation (Supplemental Figure 1F). Moreover, upon 45 h of starvation, 
4E-BP1 and S6P235/6 levels were similar in mutant and control muscles, while AMPK 
phosphorylation showed only a trend toward increase in HSALR muscle (Figure 1D). We 
next addressed whether pharmacological treatments would be sufficient to modulate 
AMPK/mTORC1 pathways in HSALR mice. Control and mutant mice were treated for 5 
days with metformin, a drug known to induce AMPK signaling. The treatment slightly 
activated AMPK in muscle from starved HSALR mice, which was accompanied by a 
decrease in S6P235/6 levels (Figure 1E). Conversely, a single injection of rapamycin, a 
canonical inhibitor of mTORC1, strongly reduced S6P235/6 levels in muscle from starved 
control and HSALR mice. Levels of AMPKP172 remained unchanged in rapamycin-treated 
mice (Figure 1F). Although no obvious change was detected in AMPK-dependent  
phosphorylation  of  TSC2  (TSC2P1387),  an upstream  inhibitor of mTORC1   
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Figure   2:   Autophagic   flux   is   impaired   in   HSALR   muscle.   (A)   Immunoblots   for   autophagy-­related  
proteins   show   accumulation   of   autophagic   substrates,   i.e.   LC3II   and   p62,   in  HSALR   TA   muscle   in   fed  
conditions  (n=3  per  group),  while  a  reduced  LC3I  to  LC3II  switch  is  observed  in  mutant  muscle  upon  24  h  
of   starvation   (St24,   n=4-­7),   compared   to   control   (Ctrl)   muscle.   (B)   HSALR   mice   expressing   GFP-­LC3  
display  increased  number  of  GFP-­positive  puncta  in  TA  muscle  compared  to  control  (Ctrl)  in  fed  conditions  
(n=3-­4),  but   reduced  accumulation  after  24  h  of  starvation   (St24,  n=3).  Scale  bar,  50  µm.  A  volume  unit  
(Vol)  corresponds  to  2.8x103  µm3.  (C)  Treatment  with  colchicine  (Colch)  leads  to  milder  changes  in  LC3II  
levels   in   TA   muscle   from   fed   and   starved   (St24)   HSALR   mice,   compared   to   control   (Ctrl)   mice.   (D)  
Immunostaining   of   muscle   sections   from   starved   control   (Ctrl)   and   HSALR   mice   reveals   no   major  
accumulation   of   p62   or   ubiquitinated   proteins   in   mutant   muscle.   Scale   bar,   100   µm.   (E)   Expression   of  
autophagy-­related   genes   is   efficiently   up-­regulated   after   45   h   of   starvation   (St45)   in  HSALR   TA  muscle.  
Data  are  normalized  to  Actn   levels  (n=3-­4).  (F-­H)  Immunoblots  reveal  limited  or  blunted  switch  from  LC3I  
to  LC3II  in  HSALR  muscle  upon  45  h  of  starvation  (St45)  (F),  rapamycin  (Rapa)  (G)  or  metformin  (MetF)  (H)  
treatments,  compared  to  controls  (Ctrl).  Data  are  relative  to  control  fed  mice  and  represent  mean  ±  SEM.  
*p<0.05,   **p<0.01,   ***p<0.001,   ****p<0.0001,   2-­way   ANOVA   with   Tukey’s   multiple   comparisons   test  
correction.    
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 (Figure 1B), these results suggest that AMPK deregulation may primarily be 
responsible for the defective response to starvation and for mTORC1 signaling 
perturbation in HSALR muscle. 
Autophagic flux is impaired in HSALR muscle. It is well established that mTORC1 and 
AMPK are key regulators of autophagy and that perturbation of their activities can lead 
to severe tissue alterations, especially in skeletal muscle [163-165]. To determine 
whether the expression of the CUG repeats impairs the autophagy process, we assessed 
the ability of HSALR muscle to induce autophagy when the mice were subjected to 
starvation. First, we evaluated levels of the soluble (LC3I) and autophagosome-
associated (LC3II) forms of the widely used LC3B (MAP1LC3 for microtubule-
associated protein light chain 3) autophagy marker. The amount of LC3II correlates 
with the intracellular accumulation of autophagic vesicles [166]. Under fed conditions, 
LC3II levels were increased in mutant muscle, which reflects either an increased 
autophagy induction or a defect in the degradation steps (Figure 2A, and Supplemental 
Figure 2A). After 24 h of starvation, a clear switch from LC3I to LC3II occurred in 
control muscle, while HSALR muscle displayed reduced changes in LC3 levels and 
LC3II/LC3I ratio (Figure 2A, and Supplemental Figure 2A). To confirm these results, 
we starved HSALR and control mice expressing the GFP-LC3 fusion protein for 24 h. In 
control muscle, a striking increase in the number of GFP-LC3-positive puncta, 
representing autophagic vesicles, was observed upon starvation (Figure 2B). In HSALR 
mice, the number of puncta was higher under fed conditions, but was significantly less 
increased upon starvation as compared to control muscle (Figure 2B). These results 
confirmed that autophagy is perturbed in HSALR muscle, which may rely on impaired 
induction and/or degradation steps. 
 To assess the status of the autophagic flux, mice were treated for 2 days with 
colchicine, a drug preventing degradation of the autophagic content. Under both fed and 
starved conditions, colchicine induced a major switch from LC3I to LC3II in control 
muscle (Figure 2C). Comparing colchicine-treated and untreated mice, we observed that 
the fold change in the LC3II/LC3I ratio was less in HSALR muscle compared to controls, 
in both fed and starved conditions (Figure 2C, and Supplemental Figure 2B). This result 
ruled out that elevated LC3II levels in fed conditions were due to increased autophagy 
induction in HSALR muscle; accumulation of autophagic vesicles was therefor  likely 
related to restricted degradation. Consistently, levels of the autophagosome cargo 
protein p62 were higher in muscle from fed mutant mice than in controls (Figure 2A). 
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Nonetheless, we detected neither p62 aggregates nor accumulation of ubiquitinated 
proteins in muscle from fed and starved HSALR mice (Figure 2D), suggesting that 
autophagy is not  completely blocked. Similarly, distribution of lysosomal vesicles, 
visualized by Lamp1  immunostaining,  was  unchanged between  2-month-old  mutant 
and control mice (Supplemental Figure 2C). Under fed conditions, increased amounts of 
p62 and LC3II were not due to abnormal transcript expression in HSALR muscle (Figure 
2E).  Moreover, expression of the Map1lc3b, Sqstm (encoding p62) and Ctsl (encoding 
Cathepsin L) genes was unchanged after 24 h of fasting, but we observed an efficient 
induction of the genes upon 45 h of starvation in both mutant and control muscles 
(Figure 2E, and Supplemental Figure 2D). It should be noted that following prolonged 
starvation, autophagy induction remained weaker in mutant muscle compared to control 
muscle (Figure 2F, and Supplemental Figure 2E). Together, these results suggest that 
autophagy deregulation in DM1 muscle results from impaired degradation in 
combination with a lowering of autophagy induction upon starvation.  
To gain further insight into autophagy deregulation, we assessed the 
phosphorylation state of Unc-51-like kinase 1 (Ulk1), as mTORC1 and AMPK 
phosphorylate and thereby inhibit or activate Ulk1, respectively [163]. Upon starvation, 
levels of the inactive form of Ulk1 (Ulk1P757) remained slightly higher in mutant muscle 
as compared to control muscle, while no major difference was observed for its active 
form (Ulk1P317 - Figure 2A, and Supplemental Figure 2A). Interestingly, rapamycin and 
metformin treatments were both sufficient to increase LC3II levels in control muscle, 
but did not induce autophagy in HSALR muscle (Figure 2, G and H, and Supplemental 
Figure 2, F and G). Hence, mTORC1/AMPK deregulation in conjunction with 
mTORC1/AMPK-independent mechanisms perturbs the autophagic flux in HSALR 
muscle at both the induction and degradation steps.  
Lastly, upon starvation, expression of the atrogenes, Trim63 and Fbxo32, was 
similarly induced in HSALR and control muscles (Supplemental Figure 2H). However, 
caspase- and trypsin-like activities associated with the proteasome system were 
increased in muscle from fed and starved mutant mice, compared to control animals 
(Supplemental Figure 2I). This is consistent with a report showing higher proteasome 
activity in muscle from a DM1 mouse model expressing 550 CTG triplets [149]. 
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Pathological involvement of autophagy impairment in DM1. To ascertain the relevance 
of the changes observed in HSALR mice for DM1 pathology, we evaluated the activation 
state of AMPK/mTORC1 signaling in muscle biopsies from three DM1 patients (P1-3) 
of 33, 34 and 49 years of age. There was no major difference in total and 
phosphorylated levels of PKB/Akt and AMPK proteins in muscle from DM1 patients 
compared to age-matched control individuals (C1/2 and  C3-5 aged of  30 and  50 years, 
respectively) (Figure 3A). Notwithstanding, we noticed that levels of the active 
phosphorylated form of p70S6K and S6 were increased in muscle biopsies from DM1 
patients compared to control individuals (Figure 3A). However, the nutritive status of 
the patients at the time of the biopsy could not be ascertained and may have influenced 
the results. For this reason, we next tested the ability of DM1 human muscle cells to 
modulate mTORC1/AMPK signaling in response to energy and nutrient deprivation. 
Fibroblasts of 3 DM1 patients (DM-L1-3) were transduced with MyoD and 
differentiated for 10 days into myotubes, before being subjected to growth medium or to 
amino acid- and glucose-deprived conditions (i.e. PBS) for 3 h. Upon deprivation, 
levels of the active phosphorylated form of PKB/Akt and S6 were strongly reduced in 
control muscle cells; there was no major activation of AMPK compared to enriched 
conditions (Figure 3B). A similar response was observed in DM1 muscle cells although 
they retained higher phosphorylation of S6 in deprived conditions compared to control 
cells (Figure 3B). In parallel, a major switch from LC3I to LC3II occurred in control 
muscle cells upon deprivation. LC3II levels were further increased in control cells 
treated with chloroquine, consistent with high autophagy induction in deprived cells 
(Figure 3C). In contrast, LC3II levels were only slightly changed when DM1 myotubes 
were submitted to deprivation, even in the presence of chloroquine, indicating that the 
autophagic flux is blocked at the induction steps (Figure 3C). Together, these data 
indicate that DM1 human muscle cells do not efficiently respond to nutrient/energy 
deprivation and display deregulation of the autophagy process. 
 To test the relevance of autophagy impairment in DM1, we looked for muscle 
alterations related to autophagy defects in muscle biopsies from DM1 patients and in 
muscle from aged HSALR mice. As previously reported [151, 167-169], vacuolated fibers 
were observed in muscle biopsy of one DM1 patient, out of the three examined (Figure 
3D). Lysosome accumulation was also detected in affected fibers from DM1 muscle 
(Figure 3D). However, in contrast to biopsies from an IBM (Inclusion Body Myositis)  
patient,  there  was no accumulation of  LC3, ubiquitinated proteins or p62 in   
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Figure  3:  Autophagy  perturbation  contributes  to  muscle  alterations  in  DM1.  (A)  Protein  lysates  from  
muscle  biopsies  of  control  individuals  (C1-­5)  and  DM1  patients  (P1-­3)  were  analyzed  for  phospho-­  (P)  and  
total   proteins   of   the   AMPK   and   PKB/Akt-­mTORC1   pathways.   (B)   MyoD   transduced   fibroblasts   from  
controls  (Ctrl)  and  DM1  patients  were  differentiated  to  myotubes  and  submitted  to  growth  medium  (GM)  or  
deprived  conditions  (PBS)  for  3  h.  Immunoblots  for  phospho-­  (P)  and  total  proteins  reveal  increased  levels  
of   S6P235/6   upon   deprivation   in   the   three   cell   lines   of   DM1   patients   (DM-­L1-­3),   compared   to   controls.  
Quantification   is   given   for   deprived   conditions;;   values   are   mean   ±   SEM   of   technical   replicates.   (C)  
Immunoblots   for   LC3  marker   show  defective   accumulation  of   LC3II   in  DM1  myotubes  upon  energy  and  
amino   acid   deprivation   (PBS)   as   well   as   with   deprived   conditions   and   chloroquine   treatment   (Chloro),  
compared   to   control   cells   (Ctrl).  Quantification  of   LC3II/LC3I   ratio   is   shown   for   two  DM1  cell   lines   (DM-­
L1/2)  in  enriched  (GM)  and  deprived  conditions;;  values  are  mean  ±  SEM  of  technical  replicates.  (D)  H&E  
stain  reveals  the  presence  of  vacuolated  fibers  (arrows)  in  muscle  biopsy  from  one  DM1  patient,  together  
with   lysosomal   accumulation   (arrowheads)   observed   by   immunostaining   in   some   affected  muscle   fibers  
(red,   lower   panel).   Scale   bar,   50   µm.   (E)  Vacuoles   (arrows)   are   observed   in  muscle   from  aging  HSALR  
mice;;   the   periphery   of   the   vacuoles   is   strongly   reactive   with   anti-­Lamp1   antibodies   (red,   lower   panel)  
indicating   accumulation   of   lysosomal   structures   in   these   regions.   High   density   of   lysosomes   is   also  
observed  in  non-­vacuolated  muscle  fibers  from  12-­month-­old  (12M)  mutant  mice  (arrowheads),  compared  
to  muscle  from  aged-­matched  control  mice  (Ctrl).  Scale  bar,  50  µm.    
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DM1 patient muscles (Supplemental Figure 3A). Consistently, LC3 levels detected by 
Western blot were similar in DM1 and control biopsies (Figure 3A). Interestingly, we 
frequently observed intracellular vacuoles in muscle from 12-month-old HSALR mice, as 
well as an accumulation of the lysosomal marker Lamp1 near the vacuolar structures 
and myonuclei (Figure 3E). Secondary antibodies alone did not react with the vacuoles 
and we did not observe such features in muscle from age-matched control mice (Figure 
3E, and Supplemental Figure 3B). Electron microscopy confirmed the presence of 
vacuoles in mutant mouse muscle: they were surrounded by dense, disorganized areas 
of contractile elements and usually limited by a single, discontinuous membrane 
(Supplemental Figure 3C). Together with the lysosome staining, these features argue for 
the accumulation of autophagic vacuoles in HSALR muscle with age. These results 
suggest that autophagy perturbation may contribute to the progressive alteration of 
muscle tissue in DM1. 
 
AMPK activation by AICAR abrogates myotonia in HSALR mice. In light of the 
deregulation of AMPK signaling in HSALR muscle, we investigated whether AMPK 
normalization would have a beneficial effect on muscle function in mutant mice. As 
readout of the disease, we evaluated myotonia by measuring the late relaxation time of 
skeletal muscle (i.e. time to reduce the maximal force from 50% to 10%) after ex vivo 
tetanic stimulation [146]. As reported previously, we observed no change in the late 
relaxation time of soleus muscle from HSALR mice compared to controls (Supplemental 
Figure 4A), whereas this parameter was strongly increased in extensor digitorum longus 
(EDL) mutant muscle (Figure 4A). Since AMPK activation by metformin has recently 
been shown to correct mis-splicing in human DM1 cells in vitro [170], 4- and 12-
month-old control and HSALR mice were treated with metformin for 10 days. Despite 
using high doses of metformin, we observed only a limited and non-reproducible effect 
of the treatment on AMPK/S6 activation state in these groups of mice analyzed under 
basal nutritive conditions (Supplemental Figure 4B). Besides, the treatment failed to 
reduce the late relaxation time of EDL muscle in mutant mice (Figure 4B) and it did not 
modify the expression and splicing of genes affected in DM1, including Clcn1 
(encoding chloride channel protein 1, Clc-1 – exon 7a inclusion) and Atp2a1 (encoding 
sarcoplasmic/endoplasmic reticulum Ca2+-ATPase 1 – exclusion exon 22) (Figure 4, C 
and D, and Supplemental Figure 4C).   
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Figure  4:  AICAR  strikingly  decreases  myotonia  in  HSALR  mice  and  reduces  mis-­splicing  in  mutant  
muscle.  (A)  In  vitro  tetanic  stimulation  (150  Hz)  of  EDL  muscle  leads  to  contraction  of  HSALR  and  control  
(Ctrl)  muscles,  with  a  strongly   increased  relaxation   time   in  mutant  muscle.   (B)  Metformin   treatment  does  
not  reduce  late  relaxation  time  of  EDL  muscle  from  4-­  and  12-­month-­old  HSALR  mice,  as  compared  to  age-­
matched  vehicle-­treated  (Veh)  mutant  mice.  n=3-­5  control  and  6-­8  HSALR  mice  per  group.  (C,  D)  Inclusion  
of  the  exon  7a  of  the  Clcn1  gene  and  the  overall  expression  of  the  gene  are  not  changed  in  muscle  from  
metformin  (MetF)-­treated  HSALR  mice,  compared  to  vehicle  (Veh)-­treated  mutant  and  control  mice  (n=3).  
(E)   Immunoblots   for   phospho-­   and   total   S6   protein   reveal   efficient   inhibition   of   AMPK-­indirect   target   in  
muscle   from   control   (Ctrl)   and   mutant   mice   treated   with   AICAR   for   7   days.   (F)   Late   relaxation   time   is  
significantly  reduced  in  EDL  muscle  from  2-­  (n=3-­4),  8-­  (n=3  Ctrl  and  6-­7  HSALR)  and  12-­  (n=4-­5)  month  
(m)-­old  HSALR   mice   which   were   treated   with   AICAR   for   7   days,   as   compared   to   age-­matched   vehicle  
(Veh)-­treated  mutant  mice.  (G-­K)  Quantitative  PCR  (G,  H)  and  end-­point  PCR  (I)  reveal  strong  reduction  in  
exon  7a  inclusion  of  the  Clcn1  gene  in  muscle  from  HSALR  mice  treated  with  AICAR,  compared  to  vehicle-­
treated   (Veh)   mutant   mice   (n=3-­5).   Protein   levels   of   Clc-­1   are   also   increased   in   mutant   muscle   from  
AICAR-­treated  mice  (J,  K  –  n=2  Ctrl  and  5  HSALR).  (L)  Quantitative  PCR  shows  similar  transcript  levels  of  
Rbm3   in  muscle  from  AICAR-­treated  and  untreated  control  and  HSALR  mice  (n=3-­4).  Data  are  relative  to  
vehicle-­treated  control  mice  (C,  D,  G,  H,  K,  L)  and  represent  mean  ±  SEM.  *p<0.05,  **p<0.01,  ***p<0.001,  
****p<0.0001,   2-­way   ANOVA   with   Tukey’s   multiple   comparisons   test   correction   (except   12M   AICAR,  
unpaired  two  tailed  Student’s  t-­test).  
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As we did not detect any effect of metformin on HSALR muscle, we tested whether 5-
aminoimidazole-4-carboxamide ribonucleotide (AICAR), an agonist of AMPK, may 
constitute an alternative strategy to target AMPK activation in muscle. Following a 
seven-day treatment with AICAR, control and mutant muscles showed a clear reduction 
in S6P235/6 levels (Figure 4E). We further confirmed that AICAR increased 
phosphorylated levels of AMPK and those of its direct target acetyl-CoA carboxylase 
(ACC) shortly after the last injection (30 min), while inhibition of the AMPK indirect 
target, S6, was only detected after 2 h in control muscle (Supplemental Figure 4D). 
Importantly, following tetanic stimuli, a strong and significant  reduction in the late 
relaxation time of EDL muscle was detected in 2- and 12-month-old AICAR-treated 
mutant mice, and myotonia was completely abrogated with AICAR in the group of 8-
month-old HSALR mice (Figure 4F, and Supplemental Figure 4E). Normalization of the 
half relaxation time (i.e. time to reduce the maximal force from 100% to 50%) of 
mutant muscle was also observed upon treatment (Supplemental Figure 4F). As mis-
splicing of the Clcn1 gene is thought to be the primary cause of myotonia in DM1 [145, 
171-173], we investigated whether the effect of AICAR was related to changes in Clcn1 
splicing. By quantitative PCR, a strong reduction in the expression of the mis-spliced 
Clcn1 transcript (containing exon 7a) was detected in muscle from AICAR-treated 
HSALR mice, while overall transcript levels of Clcn1 were unchanged compared to 
untreated mutant mice (Figure 4, G and H). We confirmed with end-point PCR that mis-
regulated Clcn1 splicing was significantly improved upon AICAR treatment (Figure 4I). 
Furthermore, AICAR led to a slight increase in Clc-1 protein levels in mutant muscle 
(Figure 4, J and K). It is worth to note that AICAR did not change splicing of the 
Atp2a1 and Camk2b genes in HSALR muscle (Supplemental Figure 4, G and H). 
Moreover, we did not detect any reduction in transcript levels of Rbm3, encoding RNA 
binding-protein 3 (Figure 4L), previously suggested to mediate the effect of AMPK 
activation on splicing [170].  
Besides its effect on myotonia, we wondered whether AICAR treatment would 
change muscle force in mutant mice. As initially reported [82], we detected neither 
muscle wasting nor reduction in total twitch (Pt) and tetanic (Po) muscle forces in 
HSALR mice compared to controls (Table 1, and Supplemental Table 1). Nonetheless, as 
cross sectional area (CSA: mass/(density*length*correction factor)) of EDL muscle was 
increased in mutant mice, specific muscle forces (sPt and sPo), representative of the 
contractile capacity of the myofibers,  were reduced in HSALR mice compared to control   
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Figure   5:   Rapamycin   improves   muscle   function   in   HSALR   mice   via   splicing-­independent  
mechanisms.  (A)  Rapamycin  (Rapa)  treatment  significantly  reduces  late  relaxation  time  of  muscle  from  4-­  
(n=4   Ctrl   and   8-­10   HSALR   per   group)   and   12-­   (n=3   Ctrl   and   5-­6   HSALR)   month-­old   HSALR   mice,   as  
compared   to   age-­matched,   vehicle   (Veh)-­treated  mutant  mice.   (B,  C)  Splicing   (B)   and   overall   transcript  
expression  (C)  of  the  Clcn1  gene  are  not  modified  in  muscle  from  rapamycin  (Rapa)-­treated  HSALR  mice,  
compared   to   vehicle   (Veh)-­treated  mutant  mice.   Values   are   relative   to   vehicle-­treated   control  mice.   (D)  
Treatment  with  AZD8055  (AZD)  for  10  days  efficiently  reduces  phosphorylation  of  mTORC1  target,  S6,  in  
control   (Ctrl)   and  HSALR   muscle,   but   does   not   change   AMPK   activation.   (E)   AZD8055   (AZD)   does   not  
reduce   late   relaxation   time  of  EDL  mutant  muscle,   compared   to   vehicle   (Veh)-­treated  mutant  mice.  n=3  
Ctrl  and  5-­8  HSALR  mice.  Data  represent  mean  ±  SEM.  **p<0.01,  ***p<0.001,  2-­way  ANOVA  with  Tukey’s  
multiple  comparisons  test  correction.  
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animals (Table 1, and Supplemental Table 1). Upon AICAR treatment, we observed that 
both total and specific forces of EDL muscle were increased in 2-month-old HSALR and 
control mice, but not in older mice (Table 1, and Supplemental Table 1). Altogether, 
these results indicate that targeting AMPK activation by AICAR improves muscle 
function in HSALR mice by reducing myotonia and potentially increasing muscle force, 
at least in part, through splicing correction.  
 
Rapamycin treatment improves muscle function in HSALR mice. Based on the abnormal 
activation of mTORC1 signaling detected in HSALR muscle, we wondered whether 
indirect mTORC1 inhibition was part of the effect of AICAR and whether direct 
mTORC1 inhibition would improve muscle function in mutant mice. To this purpose, 
we subjected 4- and 12-month-old mice to rapamycin treatment for 7 and 10 days, 
respectively. Rapamycin treatment efficiently inhibited mTORC1 signaling, as shown 
by reduced S6P235/6 levels in muscle from control and HSALR mice (Supplemental Figure 
5A). Rapamycin did not affect muscle half relaxation time (Supplemental Figure 5B), 
but significantly reduced the late relaxation time of EDL muscle from 4- and 12-month-
old HSALR mice (Figure 5A, and Supplemental Figure 5C). Moreover, we detected a 
significant increase in total and specific muscle forces in young rapamycin-treated 
mutant mice compared to vehicle-treated animals. Forces remained unchanged upon 
treatment in older mice (Table 1, and Supplemental Table S1).  
To test whether the effect of rapamycin on muscle function relied on splicing 
improvement, we assessed, by quantitative PCR, Clcn1 mis-splicing (i.e. exon 7a 
inclusion). Interestingly, rapamycin affected neither Clcn1 splicing (Figure 5B) nor the 
overall transcript expression of the gene (Figure 5C) in mutant muscle. Consistently, 
splicing of the Atp2a1 gene was also not restored in rapamycin-treated HSALR mice 
(Supplemental Figure 5D). Together, these data suggest that mTORC1 inhibition by 
rapamycin is sufficient to improve muscle function in HSALR mice likely through 
splicing-independent mechanisms.  
 Since rapamycin has been shown to impact on channel function (e.g. ryanodine 
receptor 1, RyR1) via its binding to FKBP12, we wondered whether mTORC1 
inhibition or the drug itself mediated the effect of the treatment on myotonia. Hence, 
control and HSALR mice were treated for 10 days with AZD8055, an ATP-competitive 
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inhibitor of mTORC1. We confirmed that AZD8055 strongly decreased levels of 
S6P235/6. in  control  and  mutant  muscle,  while  the activation state of AMPK remained   
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Figure  6:  AMPK  activation  by  AICAR  leads  to  nuclear  foci  dispersion  in  HSALR  muscle.  (A,  B)  H&E  
(A)  and  NADH   (B)  stains   reveal  no  major  change   in  muscle  histopathology  and  oxidative  capacity  upon  
AICAR   or   rapamycin   treatment   in   HSALR   mice.   Arrowheads   and   arrows   show   internalized   nuclei   and  
vacuoles,  respectively.  Scale  bar,  50  µm  (A),  200  µm  (B).  (C)  Immunostaining  for  type  IIA  (bright  red),  IIX  
(dark  red)  and  IIB  (green)  myosin  heavy  chains  (MHC)  reveals  no  change  in  the  respective  proportion  of  
fiber   types   in   TA   mutant   muscle   upon   AICAR   (n=3-­4   per   genotype)   or   rapamycin   (n=3-­4)   treatment,  
compared   to   vehicle-­treated  HSALR   mice   (n=6-­7).   (D)   Fluorescence   in   situ   hybridization   on   TA  muscle  
sections  with  a  Cy3-­CAG10  DNA  probe  shows  accumulation  of  nuclear  foci  in  HSALR  muscle  (arrows).  The  
number  of  stained  nuclei   is  significantly  decreased  upon  AICAR  treatment   (n=4),  but  not  with   rapamycin  
(Rapa,  n=3),  compared  to  vehicle  (Veh)-­treated  mutant  mice.  Foci  are  not  detected  in  control  (Ctrl)  muscle.  
Scale  bar,  50  µm.  Data  represent  mean  ±  SEM.  *p<0.05,  **p<0.01,  2-­way  ANOVA  with  Tukey’s  multiple  
comparisons  test  correction.  
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unchanged (Figure 5D). In contrast to rapamycin, AZD8055 had no effect on late 
relaxation time of mutant muscle (Figure 5E). Nonetheless, total and specific forces of 
EDL muscle were increased in AZD8055-treated mutant mice, as observed with 
rapamycin (Table 1, and Supplemental Table 1). Together, these results indicate that 
mTORC1 inhibition may ameliorate the contractile capacity of muscle in HSALR mice, 
while muscle relaxation improvement upon rapamycin and AICAR treatments is likely 
independent of mTORC1.  
 
AICAR, but not rapamycin, leads to nuclear foci dispersion in HSALR muscle. To further 
understand the beneficial effect of AICAR and rapamycin in HSALR mice, we 
investigated whether the treatments improved muscle function by affecting  
theproperties of the diseased muscle. First, we did not observe major changes in the 
histopathology of HSALR muscle upon 7-day AICAR or 10-day rapamycin treatment, 
compared to untreated conditions (Figure 6A). Of note, vacuoles remained present in 
muscle fibers from 12-month-old, AICAR- or rapamycin-treated HSALR mice (Figure 
6A), indicating that the treatments were not sufficient to reverse muscle alterations 
related to impaired autophagy in aging mice. As no myotonia was detected in the slow, 
soleus muscle of HSALR mice and as AICAR and rapamycin were previously shown to 
alter muscle fiber types [174, 175], we tested whether changes in muscle function upon 
treatments were related to modification of muscle metabolic and contractile capacity. 
By nicotinamide adenine dinucleotide (NADH) staining, we first observed that the 
overall oxidative property of TA muscle was unchanged in AICAR- and rapamycin-
treated mutant mice, compared to untreated animals (Figure 6B). Immunostaining 
against type I, IIA/X and IIB myosin heavy chains (MHC) was then conducted in TA 
muscle from HSALR and control mice to identify changes in muscle contractile properties 
upon treatment. Only few type I fibers were present in all the muscles analyzed (data 
not shown). Mutant muscle displayed a switch to slower fibers (i.e. increased and 
reduced proportion of IIA and IIB fibers, respectively) compared to control muscle 
(Figure 6C). However, upon AICAR or rapamycin, there was no significant change in 
the proportion of the different fiber types in comparison to vehicle-treated mice (Figure 
6C).  
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Since aggregation of (CUG)n-expanded RNA in nuclear foci is one histological 
hallmark in DM1 diseased muscle, we next wondered whether the treatments affected 
their  accumulation  in  HSALR  muscle.  To  this purpose, we performed fluorescence in   
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Table  1:  Changes   in  muscle  cross  section  area  and  tetanic   forces  upon  treatments   in  HSALR  and  
control  mice.  
  
	   Ctrl	   HSALR	  
	   Vehicle	   AICAR	   Vehicle	   AICAR	  
CSA	  EDL	  (mm2)	   	   	   	   	  
2M	   1.38	  ±	  0.02	   1.31	  ±	  0.03	   1.65	  ±	  0.05###	   1.62	  ±	  0.01###	  
8M	   1.52	  ±	  0.00	   1.70	  ±	  0.2	   1.86	  ±	  0.07	   1.70	  ±	  0.04	  
12M	   -­‐	   -­‐	   2.46	  ±	  0.07	   2.32	  ±	  0.02	  
Po	  (mN)	   	   	   	   	  
2M	   185.20	  ±	  9.01	   255.79	  ±	  9.09*	   197.91	  ±	  13.96	   279.97	  ±	  17.25**	  
8M	   285.37	  ±	  33.67	   273.71	  ±	  36.71	   288.31	  ±	  15.15	   274.39	  ±	  12.27	  
12M	   -­‐	   -­‐	   260.90	  ±	  26.53	   339.42	  ±	  24.220.07	  
sPo	  (mN/mm2)	   	   	   	   	  
2M	   134.58	  ±	  4.84	   194.73	  ±	  2.67*	   121.23	  ±	  12.16	   173.60	  ±	  11.05*	  
8M	   187.58	  ±	  22.01	   168.80	  ±	  34.37	   156.89	  ±	  11.95	   161.94	  ±	  7.34	  
12M	   -­‐	   -­‐	   107.33	  ±	  13.02	   146.46	  ±	  10.510.06	  
	   	   	   	   	  
	   Vehicle	   Rapamycin	   Vehicle	   Rapamycin	  
CSA	  EDL	  (mm2)	   	   	   	   	  
4M	   1.69	  ±	  0.12	   1.61	  ±	  0.07	   2.04	  ±	  0.07##	   1.96	  ±	  0.02##	  
12M	   1.67	  ±	  0.09	   1.50	  ±	  0.10	   1.90	  ±	  0.06	   1.77	  ±	  0.09	  
Po	  (mN)	   	   	   	   	  
4M	   180.94	  ±	  26.37	   170.07	  ±	  3.91	   193.80	  ±	  13.01	   274.48	  ±	  16.11**##	  
12M	   226.14	  ±	  28.30	   245.67	  ±	  16.07	   209.59	  ±	  30.94	   240.28	  ±	  18.95	  
sPo	  (mN/mm2)	   	   	   	   	  
4M	   114.98	  ±	  21.53	   111.32	  ±	  8.79	   99.41	  ±	  7.64	   144.37	  ±	  8.32**	  
12M	   137.66	  ±	  23.49	   168.87	  ±	  20.50	   109.78	  ±	  15.01	   137.12	  ±	  12.41	  
	   	   	   	   	  
	   Vehicle	   AZD8055	   Vehicle	   AZD8055	  
CSA	  EDL	  (mm2)	   1.24	  ±	  0.42	   1.67	  ±	  0.03	   2.09	  ±	  0.09#	   2.06	  ±	  0.04	  
Po	  (mN)	   185.19	  ±	  76.17	   241.13	  ±	  80.46	   257.96	  ±	  28.02	   353.06	  ±	  8.90	  
sPo	  (mN/mm2)	   190.13	  ±	  23.13	   192.38	  ±	  6.94	   124.30	  ±	  13.88#	   171.96	  ±	  5.22*	  
	   	   	   	   	  
 
CSA,   cross   sectional   area;;   Po,   tetanic   muscle   force.   CSA   =   weight/(1.06*length*0.44),   where   1.06  
corresponds  to  the  density  of  the  muscle  and  0.44  the  correction  factor  for  EDL  muscle.  AICAR,  2M  (n=3-­
4),  8M  (n=3  Ctrl  and  6-­7  HSALR),  12M  (n=4-­5);;  Rapamycin,  4M  (n=4  Ctrl  and  8-­10  HSALR),  12M  (n=3  Ctrl  
and   5-­6  HSALR);;   AZD8055   (n=3   Ctrl   and   5-­8  HSALR).   Values   are  mean   ±   SEM.   #   p<   0.05,   ##   p<0.01  
compared   to   control   mice   with   same   treatment;;   *   p<0.05,   **   p<0.01,   ***   p<0.001   compared   to   same  
genotype  treated  with  vehicle,  2-­way  ANOVA  with  Tukey’s  multiple  comparisons  test  correction  –  For  12M  
AICAR,  unpaired  two  tailed  Student’s  t-­test.  
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situ hybridization using a CAG10 DNA probe on TA muscle sections from mutant un-
treated- and treated-mice. Numerous foci were observed in HSALR muscle while none 
were detected in control muscle (Figure 6D). Interestingly, the number of nuclei show-
ing foci was significantly decreased in muscle from AICAR-treated mutant mice, while 
no change was observed with rapamycin (Figure 6D). Moreover, foci appeared more 
diffuse in positive nuclei from mutant muscle upon AICAR treatment, compared to un-
treated conditions (Figure 6D). Altogether, these results indicate that changes in muscle 
metabolic and contractile properties do not account for the beneficial effect of the short 
treatments applied to HSALR mice, whilst reduced muscle pathology upon AICAR-
mediated acute AMPK activation likely involves nuclear foci dispersion in the mutant 
muscle. 
Discussion  
The pathogenic mechanisms underlying DM1 disease are still not well understood and 
most investigations so far have focused on splicing defects caused by mRNA toxicity. 
In this study, we uncovered that in DM1, the AMPK and the mTORC1 pathways are 
deregulated and that the autophagic flux is perturbed in skeletal muscle. Most 
importantly, we established that pharmacological interference with AMPK/mTORC1 
signaling by AICAR or rapamycin ameliorates DM1 muscle function. 
AMPK and PKB/Akt-mTORC1 signaling are central metabolic pathways in 
muscle cells, and their deregulation has been related to muscle alterations and disease 
[164, 176, 177]. We found that DM1 muscle shows an altered response to 
energy/nutrient-deprived conditions, with impaired AMPK activation and abnormal 
activation of mTORC1 signaling. Although we have not studied the upstream 
mechanisms involved in this deregulation, mis-splicing-dependent CaMKII deficiency 
could well account for the limited AMPK activation in DM1 muscle [156, 158-161]. 
Interestingly, Jones et al. recently reported increased GSK3β levels and activity in 
HSALR muscle [178], which may also contribute to the perturbation of AMPK in DM1 
muscle [179]. In parallel, AMPK constitutes an upstream regulator of mTORC1 [180] 
and its deregulation could thus be responsible for abnormal mTORC1 activation in 
DM1 muscle cells. Nonetheless, as we did not detect changes in 4E-BP1 levels or 
mTOR phosphorylation in mutant muscle, evidence that the state of mTORC1 is 
modified in DM1 muscle and not only the activation of its downstream axis p70S6K/S6 
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is missing. Previous reports suggested that mTORC1 is inhibited in DM1 human neural 
and muscle cells [151, 153] although results were only obtained in vitro and the 
underlying mechanisms have not been investigated. Based on the abnormal splicing and 
protein trafficking of the insulin receptor in metabolic tissues in DM1 [127, 152], it has 
also been hypothesized that PKB/Akt-mTORC1 may be less responsive to insulin. 
However, results regarding the activation state of PKB/Akt signaling in DM1 human 
muscle biopsies or cells are conflicting [128, 154]. In our experiments, we did not detect 
changes in PKB/Akt activation or in the expression of Insr in HSALR muscle, suggesting 
that AMPK/mTORC1 deregulation is independent of insulin receptor deficiency.  
Autophagy as a major catabolic process essential for proteostasis has also been 
suggested to contribute to muscle alterations in DM1 [181]. The involvement of 
autophagy in DM1 was largely deduced from the presence of autophagic vesicles and/or 
accumulation of autophagic markers in DM1 cells, but usually without dynamic 
measurement of the autophagic flux [150, 151, 153, 154, 168, 169, 182]. In our study, 
we combined several methods and established that changes in LC3, increased levels of 
p62 and fiber vacuolization in muscle from older HSALR mice are caused by restricted 
autophagic flux at the degradation steps. Further, we showed that even prolonged 
starvation did not fully induce autophagy in mutant muscle. We hypothesize that 
AMPK- and mTORC1-independent mechanisms contribute to this autophagy defect, as 
rapamycin and metformin were not sufficient to normalize the flux in HSALR mice. 
Although autophagy impairment may contribute to muscle atrophy in DM1, it is 
unlikely to be the main pathogenic event, as autophagic features were scarce in DM1 
muscle biopsies, compared to diseases primarily related to autophagy defects, such as 
vacuolar myopathies.  
 Importantly, we identified that AMPK/mTORC1 deregulation likely contributes 
to alteration of muscle function in DM1. Myotonia, which is due to membrane 
hyperexcitability, is thought to be caused primarily by mis-splicing and thereby 
deficiency in the chloride channel 1 [82, 145, 171, 173]. In contrast to a recent report 
studying cultured human DM1 cells [170], we did not find any effect of metformin on 
the mis-splicing of DM1-affected genes or on the severe myotonia observed in HSALR 
mice. While we cannot rule out that changes in dosage and administration may lead to 
different results, much higher concentrations may be required to efficiently stimulate 
AMPK in rodent muscle tissue. In contrast to metformin, we found a profound effect of 
AICAR, a more potent AMPK agonist. AICAR led to a strong reduction of myotonia in 
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HSALR mice, which correlated with improved splicing of the Clcn1 gene and increased 
protein levels of the channel. While AMPK activation was related to repression of the 
RNA-binding protein Rbm3 in vitro, Rbm3 expression was unchanged in HSALR muscle 
upon AICAR treatment. As we observed dispersion of the nuclear foci formed by the 
(CUG)n-expanded RNA aggregation after AICAR treatment, the effect of AMPK 
activation on splicing may be mediated by its interaction with other RNA-binding 
proteins, such as hnRNP H, which were implicated in foci stability in DM1 [183, 184]. 
Hence, one may argue that AMPK deregulation likely contributes to pathogenesis in 
DM1 muscle by perturbing RNA-binding proteins and thereby accentuating foci 
stability and mis-splicing events [185-187]. Of note, we cannot rule out that 
amelioration of muscle relaxation also relies on splicing-independent mechanisms. In 
particular, changes in sodium and calcium-activated potassium channels or in 
Ca2+ homeostasis, which have also been suggested to contribute to myotonia in DM1 
[188-193], may mediate some of the observed effect. Consistently, AMPK has been 
shown to modulate chloride and potassium channels in several cell types, including 
cardiomyocytes [194, 195]. Such mechanisms may also contribute to the beneficial 
effect of rapamycin, as it occurs in the absence of splicing changes. Rapamycin could 
influence intracellular calcium mobilization by dissociating FKBPs (FK506-binding 
protein) from RyR1, thereby modifying channel activity [196-198].  
While muscle weakness is observed in DM1 patients, it was initially not reported 
in HSALR mice [82]. Consistently, in our study, total muscle force was not affected in 
mutant mice but we observed reduced specific muscle strength in HSALR mice. Both 
specific and total muscle forces were increased upon AICAR, rapamycin and AZD8055 
treatments in young mutant mice, which may be mediated by mTORC1 inhibition as the 
signaling was shown to modulate Ca2+ homeostasis and excitation-contraction coupling 
in skeletal muscle [199]. Myotonia reduction and increase in muscle force were not 
caused by modified metabolic and contractile properties of the mutant muscle upon the 
applied short-term treatments. However, one can hypothesize that the changes expected 
upon long-term administration of these drugs (i.e. switch toward slower fibers) may 
further positively affect DM1 muscle function. 
  In conclusion, we identified that deregulation of AMPK/mTORC1 signaling, 
together with autophagy impairment contribute to DM1-associated muscle alterations. 
We showed that treatments targeting the AMPK/mTORC1 imbalance are beneficial for 
muscle function, though to varying degrees. Whether alternative AMPK/mTORC1-
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targeting compounds, as well as changes in the dosage, administration mode or 
treatment duration may further improve muscle function remains to be investigated. As 
the drugs used in our study can target the pathways body wide, they may also be 
beneficial in other tissues and thus may represent new treatment options for DM1. 
Materials and methods  
Mice 
Homozygous mice of the mouse line LR20b carrying around 250 (CTG) repeats within 
the HSA transgene (HSALR) were obtained from Thornton et al. [82]. Mice of the 
corresponding background strain (FVB/N) were used as control. GFP-LC3:HSALR and 
GFP-LC3:FVB/N mice were obtained by crossing GFP-LC3 expressing mice [155] 
with HSALR or FVB/N mice. Mice were genotyped for HSALR transgenes by quantifying 
ACTA1 levels normalized to endogenous actin (mouse Acta1) in genomic DNA. Mice 
were maintained in a conventional SPF facility with a fixed light cycle (23°C, 12 h 
dark-light cycle). Mice were intraperitoneally injected with colchicine (Sigma, 0.4 
mg/kg) for 2 days, rapamycin (LC Laboratories) for 1 day (4 mg/kg), 7 or 10 days (2 
mg/kg), AICAR (Toronto Research Chemicals, 500 mg/kg) for 7 days, or AZD8055 
(LC Laboratories, 10 mg/kg) for 10 days. Mice were treated with metformin (Sigma-
Aldrich, 300 mg/kg) by gavage for 5 or 10 days. For starvation experiments, mice were 
sacrificed after 12 h food deprivation followed by 4 h free access to food (fed), or after 
24 h or 45 h food deprivation but free access to water (starved). In vitro force 
measurement of EDL and soleus muscles was conducted as previously described [164]. 
Half- and late-relaxation times were calculated according to Moyer et al. [146].  
 
Human muscle cells and biopsy samples 
Muscle biopsies frozen in nitrogen-cooled isopentane from 3 DM1 patients, aged 33, 34 
and 49 years and from an IBM patient were analyzed and compared to 5 control muscle 
samples from age-matched individuals showing no clinical signs of DM1 and normal 
muscle histology. MyoD-transduced fibroblasts from control individuals and patients 
were cultured in growth medium (DMEM, 10% FBS, 50 μg/mL gentamicin) at 37°C 
under 5% CO2. At confluency, transduction into myoblasts was induced by 
differentiation medium (DMEM, 50 μg/mL gentamycin, 3 μg/mL doxycycline hyclate, 
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10 μg/mL human recombinant insulin) [200]. Myotubes obtained after 10 days were 
incubated for 3 h in growth medium (refed), PBS (starved), or PBS supplemented with 
chloroquine (100 μM).  
 
Western Blotting 
Cell pellets and muscles powdered in liquid nitrogen were lysed in cold RIPA+ buffer 
(50 mM Tris HCl pH8, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% 
SDS, 1% Triton-X, 10% glycerol, phosphatase and protease inhibitors). Following 
dosage (BCA Protein Assay, Sigma-Aldrich), proteins were separated on SDS-
polyacrylamide gels and transferred to nitrocellulose membrane. Blots were blocked in 
TBS, 3% BSA, 0.1% Tween-20, incubated overnight at 4°C with primary antibodies, 
and then for 2 h with HRP-labelled secondary antibodies. Immunoreactivity was 
detected using the ECL western blot detection reagent LumiGLO (KPL) and exposed to 
Super RX-N films (Fujifilm). Protein expression was normalized to α-actinin, α-tubulin 
or the total protein of the corresponding phosphorylated form. Antibodies used are listed 
in Supplemental Material. 
 
Polymerase chain Reaction (PCR) 
Total RNAs were extracted with the RNeasy Mini Kit (Qiagen), reverse transcribed 
with the SuperScript III First-Strand Synthesis System (Invitrogen) and amplified with 
the Power Sybr Green Master Mix (Applied Biosystems) or the Hot FirePol EvaGreen 
qPCR Mix (Solis BioDyne). Expression of specific spliced or pan transcripts was 
analyzed by end-point PCR and electrophoresis, or by quantitative PCR with the Step 
One software and normalization to Actn expression. Primers are listed in Supplemental 
Material, Table S2. 
 
Histology and Immunofluorescence 
Muscles were frozen in liquid nitrogen-cooled isopentane. 8 µm muscle sections were 
stained with Hematoxylin/Eosin (H&E) or NADH, and observed with an upright 
microscope (DMR, Leica). For immunostaining, sections were unfixed or fixed with 4% 
paraformaldehyde (PFA), cold acetone or methanol; for some, microwave antigen 
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retrieval was used. Sections were then blocked in PBS, 3% BSA, incubated sequentially 
with primary and appropriate secondary fluorescent antibodies (Invitrogen), mounted 
with Vectashield medium (Vector) and observed with a Leica fluorescent microscope.  
 
GFP-LC3 puncta analysis 
For GFP-LC3 detection, mice were perfused with 4% PFA and muscles were incubated 
in 30% sucrose overnight. Cryosections were washed and mounted. Images were 
recorded using a Leica confocal microscope with 63x objective. The number of GFP-
LC3 puncta was counted on the 3D reconstructed images with Imaris (version 8.1.2) 
software. Seven to twelve image stacks were quantified for each muscle and the average 
number of GFP-LC3 puncta per volume unit defined within a single fiber (20.8 x 20.8 x 
6.5 µm3) was used for statistical analyses. All GFP quantifications were done in a 
blinded way.  
 
Fluorescence in situ hybridization (FISH) 
FISH was conducted on muscle cryosections as previously described by Batra et al. 
[201], using a Cy3-CAG10 DNA probe. Nuclear foci were observed with a Leica 
confocal microscope with 40 and 100x objectives.  
 
Statistics 
Quantitative data are displayed as mean ± SEM of independent samples, with n (number 
of individual experiments) ≥ 3. Statistical analysis of values was performed using 
Student’s t-test or two-way ANOVA test with Tukey’s multiple comparisons test 
correction, with a 0.05 level of confidence accepted for statistical significance.  
 
Study approval 
Muscle biopsies from DM1 patients were obtained from the Neuromuscular Tissue 
Bank (Department of Neurosciences, University of Padova, Padova, Italy) through the 
Telethon Network of Genetic Biobanks and the EuroBioBank, in accordance with 
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European recommendation and Italian legislation on ethics. Control and IBM human 
muscle biopsies were from the Department of Pathology, University Hospital of Basel 
(Basel, Switzerland); their use was approved by the Ethical Committee of the University 
Hospital of Basel. Human fibroblast cell lines were obtained from the platform for 
immortalization of human cells at the Institut de Myologie (Paris, France). Fibroblasts 
derived from skin biopsies were obtained from the MyoBank-AFM bank of tissues for 
research at the Institut de Myologie, a partner in the EU network EuroBioBank, in 
accordance with European recommendation and French legislation on ethics. All animal 
studies were performed in accordance with the European Union guidelines for animal 
care and approved by the Veterinary Office of the Canton of Basel city (application 
number 2601). 
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Supplemental  Figure  1:  Imbalance  in  AMPK  /  mTORC1  pathways  is  not  related  to  insulin  receptor  
(IR)-­PKB/Akt  deregulation  and  is  limited  to  muscle  tissue  in  HSALR  mice.  (A)  Simplified  scheme  of  the  
metabolic  signaling  involved  in  proteostasis  in  skeletal  muscle.  (B)  Representation  of  the  known  alternative  
splicing  of  Camk2b  mRNA  in  DM1  (exon  13  exclusion)  and  of  the  primers  used  to  quantify  its  expression.  
Quantitative  PCR  shows   increased   levels  of  Camk2b   transcript  with  exon  13  exclusion  (-­ex13)   in  HSALR  
muscle.  n=4  per  group.  (C)  Transcript  levels  of  Camk2a,  2b,  2d  and  2g  are  not  affected  in  HSALR  muscle  
(n=4).  Expression   is  normalized   to  Actn.   (D)  Splicing  of   the   Insr  gene,  corresponding   to   the  mis-­splicing  
event   in   DM1   patients,   is   not   altered   in  muscle   from   2  month-­old  HSALR   mice   (n=4).   (E)   Imbalance   in  
AMPK  and  mTORC1  signaling  is  not  observed  in  liver  from  fed  and  starved  (St24)  HSALR  mice  compared  
to  control   (Ctrl)  animals.   (F)  Loss  of  body  weight   increases   from  24  to  45  h  of  starvation   in  control   (Ctrl)  
mice  but  not  in  HSALR  mice.  Loss  is  expressed  as  a  percentage  of  the  initial  body  weight.  n=3-­4.  Data  are  
relative  to  control  (B-­D)  and  represent  mean  ±  SEM.  ****p<0.0001,  unpaired  two  tailed  Student’s  t-­test  (B);;  
*p<0.05,  2-­way  ANOVA  with  Tukey’s  multiple  comparisons  test  correction  (F).     
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Supplemental   Figure   2:   HSALR   muscles   display   impaired   autophagic   flux   and   increased  
proteasome  activity.   (A,  B)  Quantification  of   immunoblots   for   autophagy-­related  proteins   in  TA  muscle  
from   fed   and   starved   (St24)   control   (Ctrl)   and  HSALR   mice.   Mice   were   treated   with   colchicine   (CC)   to  
analyze  the  autophagic  flux.  Protein  expression  is  normalized  to  α-­actinin  (A,  n=3-­7  per  group;;  B,  n=3-­4).  
(C)  Immunostaining  for  Lamp1  protein  (red)  reveals  similar   lysosomal  distribution  in  muscle  from  fed  and  
starved   (St24)   HSALR   and   control   (Ctrl)   mice.   Scale   bar,   20   µm.   (D)   Expression   of   autophagy-­related  
genes  remains  unchanged  in  control  (Ctrl)  and  HSALR  muscle  after  24  h  of  starvation  (St24).  n=3-­4.  (E-­G)  
After  45  h  of  starvation  (St45,  E),  rapamycin  (Rapa,  F)  or  metformin  (MetF,  G)  treatment,  changes  in  LC3II  
to   LC3I   ratio   are   reduced   in   muscle   from  HSALR   mice   as   compared   to   control   (Ctrl)   mice   (n=3-­4).   (H)  
Expression  of  atrogenes  is  efficiently  induced  in  HSALR  muscle  upon  45  h  of  starvation  (St45).  Expression  
is  normalized  to  Actn  (n=3-­4).  (I)  Trypsin-­  and  caspase-­like  activities  are  increased  in  muscle  from  fed  and  
starved  (St24)  HSALR  mice,  compared  to  control  (Ctrl)  mice  in  the  same  nutritive  condition  (n=3).  Data  are  
relative  to  control  mice  in  fed  conditions  (A,  D,  E,  H,  I)  or  to  vehicle-­treated  control  mice  (B,  F,  G).  Values  
represent  mean  ±  SEM.  *p<0.05,  **p<0.01,  ***p<0.001,  ****p<0.0001,  2-­way  ANOVA  with  Tukey’s  multiple  
comparisons  test  correction.  
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Supplemental  Figure  3:  Few  autophagic   features  are  observed   in  muscle   from  DM1  patients  and  
HSALR  mice.  (A)  Muscle  biopsies  from  DM1  patients  display  no  accumulation  of  LC3  (red,  upper  panel),  
ubiquitinated   proteins   (red,  middle   panel)   or   p62   (red,   lower   panel)   by   immunostaining,   contrasting  with  
muscle  from  an  IBM  patient  (arrow).  Scale  bar,  50  µm.  (B)  Immunostaining  on  serial  muscle  sections  from  
12-­month  (M)-­old  HSALR  mice  shows  high  density  of  lysosomes,  reacting  with  anti-­Lamp1  antibodies  (red),  
at  the  periphery  of  a  vacuole;;  no  positive  staining  is  observed  in  the  negative  control  with  only  secondary  
antibodies   (red,   anti-­rat)   in   the   region   of   the   same   vacuole.   Scale   bar,   50   µm.   (C)   Electron  microcopy  
confirms  the  presence  of  vacuolar  structures  in  muscle  from  12-­month  (M)-­old  HSALR  mice.  Vacuoles  are  
limited   by   discontinuous   membrane   structures   (arrow)   and   surrounded   by   disorganized   regions   of  
contractile  materials  (arrowhead).  Scale  bar,  2  µm  for  left  panel;;  0.5  µm  for  right  panel.    
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Supplemental   Figure   4:   AICAR   and   metformin   treatments   have   distinct   effects   on   DM1   muscle  
function  and  splicing.  (A)  In  vitro  tetanic  stimulation  (120  Hz)  of  the  soleus  muscle  leads  to  contraction  of  
HSALR  and  control  muscles;;  half  and  late  relaxation  times  are  not  increased  in  mutant  soleus  muscle.  (B)  A  
ten-­day   oral   treatment   with   metformin   does   not   lead   to   reproducible   decreased   S6   phosphorylation   in  
control   (Ctrl)   and   mutant   muscles.   (C)   Splicing   and   transcript   expression   of   the   Atp2a1   gene   are   not  
changed  in  muscle  from  metformin  (MetF)-­treated  HSALR  mice,  compared  to  vehicle  (Veh)-­treated  mutant  
mice  (n=3  per  group).  (D)  Immunoblots  for  phospho-­  and  total  ACC,  AMPK,  PKB/Akt  and  S6  proteins  show  
efficient   phosphorylation   of   AMPK   and   ACC,   30   min   after   AICAR   injection   in   control   (Ctrl)   muscle.  
Phosphorylation  of  S6,  an  AMPK-­indirect   target,   is   strongly   reduced  2  h  after  AICAR   injection,  while  no  
major  change  in  PKB/Akt  activity  is  detected.  (E)  AICAR  treatment  normalizes  the  time  to  relax  of  HSALR  
muscle  upon  tetanic  stimulation  (150  Hz),  compared  to  muscle  from  vehicle-­treated  mutant  mice  (Veh).  (F)  
Half  relaxation  time  is  reduced  in  muscle  from  2  and  8  month  (m)-­old  HSALR  mice  treated  with  AICAR,  as  
compared  with  untreated  (Veh)  mutant  mice  (n=3-­4  Ctrl  and  4-­7  HSALR).  (G,  H)  Mis-­splicing  and  transcript  
expression  of  Atp2a1  (G)  and  Camk2b  (H)  genes  are  not  changed  in  muscle  from  AICAR-­treated  HSALR  
mice,  compared   to  vehicle   (Veh)-­treated  mutant  mice  (n=3-­4).  Values  represent  mean  ±  SEM.  **p<0.01,  
***p<0.001,  ****p<0.0001,  2-­way  ANOVA  with  Tukey’s  multiple  comparisons  test  correction.  
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Supplemental   Figure   5:   Rapamycin   treatment   efficiently   inhibits   mTORC1   signaling   but   impacts  
neither   on   half   relaxation   time   nor   on   splicing.   (A)   Immunoblots   for   phospho-­   and   total   S6   proteins  
reveal  efficient  mTORC1  inhibition  in  4-­  and  12-­  month(M)-­old,  rapamycin  (Rapa)-­treated  control  (Ctrl)  and  
HSALR   mice.   (B)   Half   relaxation   time   remains   unchanged   upon   rapamycin   (Rapa)   treatment   of   HSALR  
mice,   as   compared   to   vehicle   (Veh)-­treated   mutant   mice   (n=3-­4   Ctrl   and   5-­10  HSALR   per   group).   (C)  
Rapamycin   treatment   strongly   reduces   the   time   to   relax   of  HSALR  muscle   upon   tetanic   stimulation   (150  
Hz),   compared   to   muscle   from   vehicle   (Veh)-­treated   mutant   mice.   (D)   Rapamycin   treatment   does   not  
change   splicing   and   expression   of   the  Atp2a1   gene   in  mutant  mice   (n=3-­4).   Values   represent  mean   ±  
SEM.  *p<0.05,  ***p<0.001,  2-­way  ANOVA  with  Tukey’s  multiple  comparisons  test  correction.  
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Supplemental  Table  1:  Changes  in  EDL  muscle  mass  and  twitch  forces  upon  treatments  in  HSALR  
and  control  mice.  
 Ctrl HSALR 
 Vehicle AICAR Vehicle AICAR 
EDL mass/BW (‰)     
2M  0.44 ± 0.01 0.42 ± 0.01 0.51 ± 0.03# 0.48 ± 0.01 
8M  0.40 ± 0.02 0.42 ± 0.03 0.45 ± 0.03 0.36 ± 0.02 
12M - - 0.40 ± 0.01 0.38 ± 0.02 
Pt (mN)     
2M 15.40 ± 1.45 22.04 ± 0.84** 12.22 ± 0.50 25.14 ± 1.16*** 
8M 30.68 ± 5.08 29.93 ± 3.21 24.02 ± 1.35 25.85 ± 1.51 
12M - - 29.27 ± 2.86 37.50 ± 1.480.06 
sPt (mN/mm2)     
2M 11.18 ± 0.92 16.84 ±1.03** 10.51 ± 0.60 15.58 ± 0.72** 
8M 20.16 ± 3.33 18.06 ± 2.52 13.08 ± 1.02# 15.24 ± 0.86 
12M - - 12.01 ± 1.39 16.18 ± 0.64* 
     
 Vehicle Rapamycin Vehicle Rapamycin 
EDL mass/BW (‰)     
4M 0.38 ± 0.02 0.37 ± 0.02 0.42 ± 0.02 0.43 ± 0.01 
12M 0.36 ± 0.03 0.33 ± 0.02 0.38 ± 0.02 0.32 ± 0.03 
Pt (mN)     
4M 20.58 ± 1.69 17.77 ± 0.80 19.61 ± 1.55 29.70 ± 2.23**## 
12M 22.40 ± 4.12 19.17 ± 0.35 17.69 ± 3.92 20.51 ± 2.18 
sPt (mN/mm2)     
4M 12.50 ± 1.71 11.08 ± 0.54 9.71 ± 0.89 15.23 ± 1.18** 
12M 13.72 ± 3.08 13.93 ± 1.25 9.26 ± 1.97 11.77 ± 1.46 
     
 Vehicle AZD8055 Vehicle AZD8055 
EDL mass/BW (‰) 0.37 ± 0.02 0.34 ± 0.02 0.42 ± 0.02 0.41 ± 0.01 
Pt (mN) 32.01 ± 3.43 31.53 ± 0.54 26.58 ± 2.68 35.55 ± 0.64** 
sPt (mN/mm2) 19.85 ± 3.42 18.84 ± 0.07 10.60 ± 2.31# 17.32 ± 0.44* 
     
 
BW,   body   weight;;   Pt,   twitch   force.   AICAR,   2M   (n=3-­4),   8M   (n=3   Ctrl   and   6-­7   HSALR),   12M   (n=4-­5);;  
Rapamycin,  4M   (n=4  Ctrl  and  8-­10  HSALR),  12M   (n=3  Ctrl  and  5-­6  HSALR);;  AZD8055   (n=3  Ctrl  and  5-­8  
HSALR).  Values  are  mean  ±  SEM.  #  p<  0.05,  ##  p<0.01  compared  to  control  mice  with  same  treatment;;  *  
p<0.05,   **   p<0.01,   ***   p<0.001   compared   to   same   genotype   treated   with   vehicle,   2-­way   ANOVA   with  
Tukey’s  multiple   comparisons   test   correction   –   For   12M  AICAR:   *   p<0.05   compared   to   same   genotype  
treated  with  vehicle,  unpaired  two  tailed  Student’s  t-­test.  
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Supplemental  Table  2:  List  of  primers.  
  
Gene   Forward  primer   Reverse  primer  
ACTA1  (human)   5'-­CGAGACCACCTACAACAGCA-­3'   5'-­GGCATACAGGTCCTTCCTGA-­3'  
Acta1  (mouse)   5'-­CCGGAAAGAAATCTCAACCA-­3'   5'-­CCAAGTCCTGCAAGTGAACA-­3'  
Actn   5'-­CTGGTCTTCGACAACAAGCA-­3'   5'-­TTGTCAGGATCTGGGTCTCC-­3'  
Atp2a1  +ex22   5'-­  GCCCTGGACTTTACCCAGTG-­3'   5'-­ACGGTTCAAAGACATGGAGGA-­3'  
Atp2a1  pan   5'-­  GCCCTGGACTTTACCCAGTG-­3'   5'-­CCTCCAGATAGTTCCGAGCA-­3'  
Camk2a   5'-­TTTGCCCTCTTCAGGCTTTA-­3'   5'-­GTGGACAGGGGCATGTTAG-­3'  
Camk2b  -­ex13   5'-­TTTCTCAGCAGCCAAGAGTTT-­3'   5'-­TTCCTTAATCCCGTCCACTG-­3'  
Camk2b  pan   5'-­GCACGTCATTGGCGAGGA-­3'   5'-­ACGGGTCTCTTCGGACTGG-­3'  
Camk2d   5'-­CTGGCACACCTGGGTATCTT-­3'   5'-­ATCCCAGAAGGGTGGGTATC-­3'  
Camk2g   5'-­ACCGACGACTACCAGCTTTTC-­3'   5'-­GCAGCATATTCCTGCGTAGATG-­3'  
Ctsl   5'-­GTGGACTGTTCTCACGCTCA-­3'   5'-­TCCGTCCTTCGCTTCATAGG-­3'  
Clcn1  +ex7a   5'-­GGGCGTGGGATGCTACTTTG-­3'   5'-­  AGGACACGGAACACAAAGGC-­3'  
Clcn1  pan   5'-­CTGACATCCTGACAGTGGGC-­3'   5'-­  AGGACACGGAACACAAAGGC-­3'  
Clcn1  (end-­point)   5'-­GGAATACCTCACACTCAAGGCC-­3'   5'-­CACGGAACACAAAGGCACTGAATGT-­3'  
Fbxo32   5'-­CTCTGTACCATGCCGTTCCT-­3'   5'-­GGCTGCTGAACAGATTCTCC-­3'  
GFP  (multiplex)  
  
5'-­ATAACTTGCTGGCCTTTCCACT-­3'  
  
5'-­CGGGCCATTTACCGTAAGTTAT-­3'  
5'-­GCAGCTCATTGCTGTTCCTCAA-­3'  
Insr  +ex11   5'-­TATGACGACTCGGCCAGTGA-­3'   5-­ACCATTGCCTGAAGAGGTTT-­3'  
Insr  pan   5'-­ATGGGCTTCGGGAGAGGAT-­3'   5'-­GGATGTCCATACCAGGGCAC-­3'  
Map1lc3b   5'-­CACTGCTCTGTCTTGTGTAGGTTG-­3'   5'-­TCGTTGTGCCTTTATTAGTGCATC-­3'  
Rbm3   5'-­CTTCTGCCATGTCGTCTGAA-­3'   5'-­TGGGTTTGTGAAGGTGATGA-­3'  
Sqstm   5'-­GCTCAGGAGGAGACGATGAC-­3'   5'-­AGAAACCCATGGACAGCATC-­3'  
Trim63   5'-­ACCTGCTGGTGGAAAACATC-­3'   5'-­AGGAGCAAGTAGGCACCTCA-­3'  
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Supplemental Methods 
 
Antibodies 
The following antibodies were used for immunoblotting or immunoflurescence: 
PKB/Akt (#9272), Phospho-AktSer473 (#4058), S6 (#2217), Phospho-S6Ser235/236 (#2211), 
LC3B (#2775), AMPKα (#2532), Phospho-AMPKαThr172 (#2531), Ulk1 (#8054), Phos-
pho-Ulk1Ser757 (#6888), Phospho-Ulk1Ser317 (#6887), mTOR (#2972), Phospho-
mTORSer2448 (#2971), 4E-BP1 (#9452), Tuberin/TSC2 (#3635), Phospho-
Tuberin/TSC2Ser1387 (#5584), Phospho-CaMKIIThr286 (#12716), LKB1 (#3047), TAK1 
(#5206), p70S6K (#9202), Phospho-p70S6KThr389 (#9209) from Cell Signaling; α-
Actinin (A5044) from Sigma; p62 (GP62C) from Progen; α-Tubulin (ab15246), Lam-
inin (ab11575 and ab11576), Lamp1 (AD4B) from Abcam; CaMKII (C-20) from Santa 
Cruz; MHCIIA (A4.74) and IIB (BF-F3) from DSHB. Clc-1 antibody was a generous 
gift from Prof. Thomas Cooper (Baylor College of Medicine, USA) [173]. HRP-tagged 
and fluorescent secondary antibodies were from Abcam and Jackson Immunoresearch.  
 
Proteasome activity assay 
Protein extracts and acquisition of proteasome activity using the Proteasome-Glo 3-
Substrate System (Promega) was described before by Strucksberg et al. [202]. 
 
Transmission electronic microscopy (EM) 
EM analysis was conducted on ultra-thin (70 nm) sections of gastrocnemius muscle, as 
previously described [203]. Sections were stained with uranyl acetate and lead citrate, 
and observed on electron microscope (Philips CM100).   
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Figure   7:   Low-­protein   diet   improves   muscle   function   in   aging,   but   not   young   HSALR   mice.   (A)  
Significant  loss  of  body  weight  is  observed  at  the  end  of  the  4  weeks  low-­protein  diet  (LPD)  in  9  month-­old  
HSALR   and  control  mice,   but   not   in   young  mice,   as   compared   to  age-­matched  mice   fed  with   chow  diet.  
Values  are  mean  ±  SEM;;  *p<0.05,  ***p<0.001,  ****p<0.0001.  (B)  Four  weeks  LPD  administration  does  not  
lead   to  major   changes   in  AMPK  and  mTORC1  signalling   in  muscle   from  4  and  9  month   (M)-­old   control  
(Ctrl)  and  HSALR  mice.  (C  -­  D)  LPD  reduces  half  (C)  and  late  (D)  relaxation  times  of  EDL  muscle  from  9  
month-­old  HSALR  mice  compared   to  mutant  mice   fed  with  chow  diet.   (E  -­  H)  Protein   restriction  does  not  
reduce  mis-­splicing   (E)   and   transcript   expression   (F)   of   the  Clcn1   gene   nor   does   it   change   alternative  
splicing   (G)  and  expression   (H)  of   the  Atp2a1   gene.   (I   -­   J)   LPD  does  not   improve  specific   tetanic   force  
(sPo)  (I)  and  specific  twitch  force  (sPt)  (J)  of  muscle  from  4  and  9  month-­old  HSALR  mice.  Values  are  mean  
±  SEM;;  *p<0.05,  **p<0.01,  ***p<0.001,  ****p<0.0001.  (K)  General  histology  observed  with  H&E  stain  is  not  
changed   in   muscle   from   9   month-­old  HSALR   mice   fed   for   4   weeks   with   LPD.   Scale   bar,   200   µm.   (D)  
Specific  twitch  force  (sPt)  is  unchanged  in  EDL  muscle  from  4  and  9  month-­old  HSALR  mice  fed  with  LPD,  
as  compared  with  mutant  mice  fed  with  chow  diet.  Data  are  mean  ±  SEM.    
  
  
 65 
 
3.2 Complementary results 
 3.2.1 Low-protein diet improves myotonia in older HSALR mice  
AMPK and mTORC1 are major sensors of the nutrient status of the cell: nutrient 
deprivation and more specifically protein restriction induce AMPK signalling and 
inhibit mTORC1. Given that drugs targeting AMPK activation or mTORC1 inhibition 
improved muscle function in HSALR mice, we investigated whether protein restriction 
would also have a beneficial effect on muscle function. To this end, we fed 4- and 9-
month-old mice during 4 weeks with a low-protein diet (LPD), containing only 5% 
proteins; reference groups were fed with standard chow diet with 20% proteins. LPD 
led to a significant loss of body mass only in the older control and mutant mice, while 
body weight was not affected in young animals (Figure 7A). Interestingly, as observed 
with prolonged starvation, aged HSALR mice were more resistant to mass loss with LPD 
than controls (Figure 7A). Of note, no reliable change in the activation state of AMPK 
and mTORC1 signalling could be detected in muscle from LPD-fed mice compared to 
chow-fed animals, at the time of sacrifice (i.e. at daytime - Figure 7B). Importantly, 
while LPD did not modify muscle relaxation in 4 month-old mutant mice, it 
significantly reduced half and late relaxation times of EDL muscle from aging HSALR 
mice, compared to age-matched mutant mice on normal chow diet (Figure 7C, D). This 
differential effect of the dietary treatment was consistent with the stronger response of 
9-month-old mice to protein restriction compared to young animals. Despite the effect 
of LPD on myotonia in aging mutant mice, we found no change in the expression or the 
splicing of the Clcn1 and Atp2a1 genes (Figure 7E - H). Moreover, LPD had no effect 
on specific muscle force (Figure 7I - J) and muscle histology (Figure 7K) in control and 
mutant mice. Thus, these results underline that splicing-independent mechanisms 
targeted by dietary approaches may have beneficial effects on muscle function in DM1 
disease. 
 3.2.2 FoxO signalling is altered in HSALR muscle 
FoxO transcriptions factors are known to be negatively regulated by Akt, while AMPK 
promotes their activity. Furthermore, FoxO induces the expression of different 
autophagy genes as well as atrogens, which are required for sustained autophagy flux 
and UPS activation. In light of the obtained results regarding blunted AMPK signalling, 
 66 
 
 
Figure  8:  Foxo3a  is  deregulated  in  HSALR  muscle.  Foxo3a  total  protein  expression  and  Foxo3aP318/321  
levels  are  potentially  increased  in  fed  and  starved  mutant  muscle.  
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altered autophagic flux and increased proteasomal activity in HSALR muscle, we 
suspected that FoxO might as well be deregulated in mutant muscle. Preliminary 
western blot analysis revealed that protein levels of FoxO3a are increased in HSALR 
muscle, in both fed and starved conditions (Figure 8). In control muscle, the Akt-
dependent inhibitory phosphorylation of FoxO3a (sites Ser318/321) showed a 
decreasing trend upon starvation. In contrast, levels of Foxo3aP318/321 were increased in 
mutant muscle compared to controls and did not show reduction upon fasting. As the 
ratio between Foxo3aP318/321 and total FoxO3a was not changed comparing mutant to 
control muscle, one can hypothesize that accumulation of the inactive form of FoxO3 is 
related to its increased protein expression, rather than excessive inhibition by Akt 
(Figure 8). This would be consistent with the effective inhibition of Akt detected in 
muscle from starved HSALR mice (Figure 1). Hence, FoxO signalling might as well be 
altered in DM1 and may contribute to the deregulation of catabolic processes in the 
diseased muscle. Further investigations remain to be conducted in order to clarify the 
activation state of FoxO signalling and the mechanism leading to its potential 
deregulation. In the short term, we will analyze the localization of FoxO by 
immunohistochemical analysis on muscle sections as FoxO nuclear import parallels its 
activation. qPCR will also be performed in order to detect potential changes in FoxO 
transcriptional expression. Lastly, examination of other phosphorylation sites (e.g. 
Foxo3aP413)), which are phosphorylated by AMPK and/or trigger FoxO activity, may 
furnish more information about FoxO status in HSALR muscle. 
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4. Discussion and Outlook 
To date, the detailed mechanism underlying the multisystemic DM1 pathology is still 
not well understood and most investigations and therapeutic developments have focused 
on splicing defects caused by mRNA toxicity. In the course of my PhD studies, I 
investigated whether deregulation of key metabolic components may contribute to DM1 
pathogenesis and may constitute novel potential therapeutic targets. I identified that 
DM1 pathology is associated with a perturbation of AMPK and mTORC1 signalling in 
skeletal muscle as well as with an impairment of the autophagic flux. Normalization of 
AMPK and/or mTORC1 pathway through pharmacological or dietary approaches 
resulted in improved muscle performance outcomes and in markedly decreased 
myotonia in HSALR mice. Of note, activation of AMPK signalling by the AMPK-agonist 
AICAR in HSALR muscle, led to a substantial reduction of myotonia, together with 
partial correction of Clcn1 mis-splicing. These findings nicely illustrate the involvement 
of abnormal AMPK-mTORC1 signalling in DM1 muscle pathophysiology and point to 
AMPK-mTORC1 modulation as potential therapeutic strategy in the DM1 context.  
4.1 Deregulation of central metabolic pathways in DM1 muscle 
The proper interplay between the two protein kinases AMPK and mTORC1, that sense 
the energy and nutrient status of the cell, determines the balance between anabolic and 
catabolic processes and therefore plays a major role in order to maintain regular muscle 
function [33, 204]. The fact that deregulation of Akt/PKB-mTORC1 and AMPK 
pathways has been related to the pathogenesis of several muscle diseases together with 
different reports suggesting a potential alteration of Akt/PKB-mTORC1 signalling in 
human DM1 cells, patient biopsies as well as in DM1 mouse models, prompted us to 
investigate the signalling characteristics of these central metabolic actors in DM1 
muscle [21, 22, 30, 31, 48-50, 52, 53]  
 4.1.1 Abnormal AMPK-mTORC1 status in HSALR skeletal muscle 
I identified an impaired activation of AMPK in HSALR muscle upon energy deprivation. 
Even after prolonged starvation AMPK activity was still reduced in mutant mice 
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compared to control mice, suggesting that the response to energy deprivation might be 
deteriorated or delayed in HSALR muscle. We further analyzed the activity of mTORC1, 
an indirect downstream target of AMPK. The increased phosphorylation and cellular 
accumulation of mTORC1 downstream targets, including p70S6k and S6, strongly 
suggests augmented mTORC1 activity in HSALR skeletal muscle. However, the 
phosphorylation status of mTOR was unchanged. Moreover, 4E-BP1 levels showed no 
difference between mutant and control mice, which could be due to the diverging 
regulation of mTORC1 targets [205]. AMPK-dependent TSC2 phosphorylation was 
neither altered in HSALR muscle. Though, further experiments are required, such as 
analysis of raptor phosphorylation status, in order to determine whether mTORC1 is 
effectively deregulated. 
Since DM1 patients display mis-splicing and abnormal protein trafficking of IR, 
an upstream regulator of the Akt/PKB-mTORC1 pathway, we suspected a connection 
between deregulated IR signalling and altered AMPK-mTORC1 activity in HSALR 
muscle [95, 127, 206]. However, an involvement of IR deregulation seems to be 
unlikely, as IR mis-splicing is not reproduced in HSALR mice. Previously, slight changes 
in the splicing of Insr were only reported in soleus muscle from aging mice of another 
DM1 mouse model [206]. Moreover, no major change in the levels and activation of 
Akt/PKB was detected comparing control and mutant mice, thus indicating that 
mTORC1 deregulation in HSALR mice is independent of the proposed Akt/PKB 
alteration [53, 127, 128].  
DM1 patients commonly exhibit metabolic disturbances including high serum 
triglycerides and LDL (low-density lipoprotein) cholesterol levels, elevated body fat 
content and insulin resistance [207]. However, these global metabolic perturbations are 
most likely not arising in the muscle specific HSALR mouse model and are probably not 
involved in altering the central metabolic signalling in HSALR muscle tissue. 
Nevertheless, we cannot exclude that the muscle specific expression the (CTG)n repeat 
expansion in in HSALR mice triggers metabolic alterations that may contribute to whole 
body metabolic deregulation. Therefore further experiments remain to be conducted in 
order to investigate the contribution of diseased muscle to body-wide metabolic changes 
observed in DM1 patients. 
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 4.1.2 Mechanisms involved in AMPK and mTORC1 deregulation 
Dietary and pharmacological treatments normalize abnormal AMPK-mTORC1 
signalling in HSALR mice 
I tested prolonged starvation and different pharmacological compounds in order to 
assess their ability to normalize abnormal AMPK-mTORC1 signalling in HSALR muscle. 
Long-lasting food restriction was able to normalize mTORC1 but not AMPK signalling, 
suggesting that impaired AMPK activation is more affected than mTORC1 signalling in 
HSALR mice. In addition, mutant mice were protected from extensive weight loss 
compared to controls, which might be linked to the deregulation of metabolic signalling 
in HSALR muscle. Metformin, an anti-diabetic drug known to stimulate AMPK activity 
[208], tended to normalize AMPK status in muscle from starved HSALR mice, and 
further slightly ameliorated deviant mTORC1 activation in mutant muscle. AICAR, 
another AMPK activator, proved to be even more effective in muscle, with a high but 
transient phosphorylation of AMPK followed by a strong inhibition of mTORC1 
activity. Rapamycin was as well sufficient to reverse mTORC1 activation, but did not 
restore AMPK status. Since AMPK was shown to be an upstream regulator of mTORC1 
[209], one can hypothesize that AMPK deregulation is a primary event in HSALR mice 
and is responsible for the abnormal activation of mTORC1. 
Potential mechanisms leading to primary AMPK deregulation in DM1 muscle  
Protein levels of AMPK-activating kinases LKB1 (serine/threonine liver kinase B1) and 
TAK1 (transforming growth factor β-activated kinase-1) [210, 211] were unchanged in 
HSALR muscle. However, I could not yet determine whether levels of the active 
phosphorylated form of these kinases were altered in mutant muscle. Therefore we 
cannot exclude their potential involvement in the deregulation of AMPK. In order to 
further investigate the cause for impaired AMPK signalling, we will evaluate the 
activity status of the AMPK-upstream kinases LBK1, TAK1 and CAMKK2 
(calcium/calmodulin-dependent protein kinase kinase 2) [212]. Moreover, measurement 
of AMP:ATP levels in muscle from control and mutant mice in fed and starved 
conditions will allow us to judge whether altered energetic status in HSALR muscle is the 
cause for blunted AMPK activation [213].  
Of note, CaMKII that was reported to regulate AMPK activity [214-216], is 
composed of different isoforms, including CamkIIα CamkIIβ, CamkIIδ and CamkIIγ 
that are known to be abnormally spliced in DM1 context [156, 217, 218]. In fact, we 
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could confirm the decreased inclusion of exon 13 of Camk2b transcript in HSALR muscle 
[137, 217]. Additionally, CaMKII isoforms exhibited a severely altered pattern of 
expression and phosphorylation, suggesting potential alteration of the other isoforms. It 
has alternatively been suggested that CaMKII activates and inhibits AMPK, but the 
exact mechanism underlying the regulation of AMPK by CaMKII in skeletal muscle 
remains unknown [219-222]. Therefore, altered AMPK signalling in HSALR muscle may 
be related to abnormal CaMKII expression, although additional investigations need to 
be conducted. In particular, potentially altered splicing events in the different Camk2 
pre-mRNAs will be examined. Moreover, analyses of transfected DM1 cells expressing 
constitutively active isoforms of CAMKII as well as electroporation of HSALR muscle 
introducing active CAMKII isoforms, may allow us to evaluate their effect on AMPK 
signalling in HSALR muscle. 
Previously, increased GSK3β levels were detected in HSALR mice, which could 
provide an alternative explanation for the altered AMPK-mTORC1 signalling [83]. 
GSK3β is implicated in the regulation of these pathways [223, 224], however it is not 
clear whether its deregulation could constitute the primary event for AMPK/mTORC1 
imbalance, as GSK3β was shown to inhibit AMPK but also mTORC1 [223-226]. 
Moreover, AMPK and mTORC1 were also shown to regulate GSK3β activation making 
it difficult to render a statement about GSK3β impact on the altered signalling [227-
229].  
 4.1.3 Augmented mTORC1 activity in human DM1 muscle? 
In conformity with the results obtained in mice, muscle biopsies and MyoD-transduced 
fibroblasts from DM1 patients presented elevated activation of some mTORC1 targets. 
Nonetheless the in vitro energy deprived condition did not allow us to detect AMPK 
activation in control cells. Therefore, it is not feasible to make a meaningful statement 
about AMPK signalling in DM1 cells. Further adjustment of the protocols for in vitro 
experiments may help to conclude on the status of AMPK in human DM1 muscle cells. 
Moreover, analysis of additional biopsies with standardized nutritive status of the 
patients at the moment of the biopsy may also bring further insight on the involvement 
of AMPK-mTORC1 deregulation in the pathology. It is known that the HSALR mouse 
model does not reproduce all aspects of DM1 pathology, e.g. insulin receptor mis-
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splicing, which may further impact on the state of these signalling in DM1 human 
muscle. 
4.2 Abnormal activity of cellular degradation systems in DM1 
context 
Reduced Akt/PKB-mTORC1 signalling has been linked previously to abnormal 
autophagic flux in DM1 [52, 53, 129]. However, the dynamics of the autophagic flux in 
DM1 context have never been precisely investigated and generally increased autophagy 
was spuriously suggested from increased levels of different autophagy markers [31, 52, 
53, 129]. At the same time, some reports have presumed that elevated autophagic flux 
contributes to muscle atrophy in DM1 [31, 52, 53]. 
 4.2.1 Abnormal autophagic flux and proteasomal activity in HSALR muscle 
Consistent with the observed AMPK-mTORC1 deregulation, being key regulators of 
autophagy, we detected impaired autophagic flux in HSALR muscle. By combining 
several approaches, we observed that both autophagy induction and the degradation 
steps are deregulated in mutant muscle. Fed HSALR mice displayed increased LC3II 
levels, pointing to limited degradations steps, however only in a moderate extent as 
there were no obvious aggregates of the autophagy and lysosomal markers p62 and 
LAMP-1 in muscle from young mutant mice [25, 230]. Upon energy deprivation, 
autophagy was not efficiently induced as the LC3I to LC3II switch was generally less 
pronounced in HSALR mice compared to controls. Colchicine treatment induced a major 
switch of LC3I to LC3II in fed and starved control mice. LC3II also accumulated in 
mutant mice after colchicine treatment, however the fold change of the LC3II/LC3I 
ratio was less pronounced in HSALR mice compared to control mice, further underlining 
the degradation defect in fed conditions as well as the induction defect in deprived 
conditions.  
Although deregulation of AMPK and mTORC1 is likely to be involved in such 
autophagy impairment, alternative mechanisms may also contribute to these defects 
since the mTORC1-AMPK modulating agents, rapamycin and metformin, were not 
sufficient to normalize the flux in mutant muscle. In aged HSALR mice, histological 
alterations related to autophagy impairment became obvious, as vacuoles were 
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frequently observed in mutant muscle fibres. The abnormal lysosomal distribution 
present in 12 month-old but not in young mice supports the hypothesis that these 
histological features arise in aged animals in consequence of deregulated autophagy 
process. 
In agreement with a previous study [22], we also detected an increase in some 
proteasomal enzymatic activities in HSALR muscle. It is unlikely that AMPK 
deregulation in mutant muscle contributes to elevated proteasomal activity as blunted 
AMPK would rather reduce the activity of FoxO transcription factors, which are central 
regulators of the proteasome [23]. Preliminary results suggest that FoxO signalling may 
be altered in mutant muscle, although further investigations, as mentioned in the part 
3.2.2, are required to confirm this hypothesis. Since we did not detect major changes in 
the expression of atrogens and autophagy-related genes, one may argue however the 
signalling may not be responsible for the deregulation of the catabolic processes. 
Therefore, additional processes might as well participate in the deregulation of 
proteasome activity in mutant muscle. Examination of other signalling pathways 
involved in proteasome activity regulation may help to shed light into the mechanisms 
linked to proteasome activation in HSALR muscle. Moreover energy imbalance may 
impact on ATP-dependent proteasome activity, thus measurement of AMP:ATP levels 
in muscle of mutant and control mice may furnish supplemental information. 
Together these data show that HSALR muscle exhibit a moderate deregulation of 
the protein degradation system. This includes a defective or delayed response to energy 
deprivation with impaired autophagy induction, restricted autophagy-related 
degradation and increased proteasomal degradation, which are altogether most likely 
contributing to the progressive muscle alterations seen in mutant muscle.  
 4.2.2 Deregulated autophagy in DM1 human muscle 
In conformity with the results obtained in HSALR mice, we observed an abnormally 
regulated autophagy flux in DM1 human muscle cells. Energy restriction and blockage 
of the degradation steps by chloroquine treatment uncovered that there is a fundamental 
difference in autophagy flux comparing control and DM1 cells. These treatments were 
not able to induce any increase in LC3II levels in DM1 human muscle cells, illustrating 
a major defect in autophagy induction in response to energy deprivation. There was no 
indication for diminished autophagic degradation steps in DM1 cells, as the flux was 
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strongly blocked at the induction. Similar to HSALR muscle, few vacuolated fibres were 
observed in the muscle biopsy from one DM1 patient. Nevertheless, accumulation of 
p62, LC3 and ubiquitinated proteins, commonly observed in autophagy related muscle 
diseases, was absent in DM1 muscle indicating that deregulated autophagic flux might 
be involved but not central to DM1 muscle pathophysiology. 
In summary, autophagy flux is likely perturbed in DM1 at the induction and 
degradation steps, although they seem to be altered at different degree in vitro in DM1 
human muscle cells and in vivo in DM1 mice. It is difficult to judge whether the 
difference obtained between HSALR muscle and DM1 cells is due to in vitro vs. in vivo 
conditions, due to differential regulation of the autophagy flux in human vs. rodent, or 
due to specific disease-related deregulations, such as IR mis-splicing, which are not 
reproduced in the HSALR model and that may impact on autophagy. 
4.3 Effect of pharmacological and dietary treatments targeting 
AMPK and mTORC1 signalling on DM1 muscle function 
Pursuing the hypothesis that deregulated AMPK-mTORC1 signalling is of major 
importance for muscle pathogenesis in DM1, we assumed that normalization of these 
pathways might lead to an improvement of muscle function in HSALR mice. One of the 
most important results of this study is the identification of the deregulation of AMPK 
and mTORC1 activity, which may be of paramount importance in the alteration of 
muscle function in DM1. We demonstrate that normalization of AMPK and mTORC1 
signalling is sufficient to improve muscle function via splicing-dependent and -
independent mechanisms, hence opening new avenues regarding therapeutic options for 
the disease. 
 4.3.1 AICAR improves muscle performance in HSALR mice through splicing-
dependent mechanisms 
AICAR but not metformin significantly reduces myotonia through corrected Clcn1 
splicing 
The AMPK-activating drug metformin was our first choice in order to assess its effect 
on HSALR muscle function, as it is known to be a well-tolerated drug that is commonly 
used to treat type 2 diabetes patients [231]. However, metformin treatment had no 
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positive effect on muscle function in HSALR mice and did not correct DM1-associated 
mis-splicing in mutant muscle. By contrast, AICAR, the second AMPK-stimulating 
drug we tested, markedly reduced late relaxation time in young and old HSALR mice and 
completely abrogated myotonia in 8 month-old animals. At the same time we detected 
increased ClC-1 protein levels together with improved splicing of Clcn1 mRNA. This is 
most likely the reason for the strong reduction of the late-relaxation time, as myotonia 
in DM1 is thought to be primarily caused by the mis-splicing and thereby deficiency of 
ClC-1 [82, 84, 100, 101]. Surprisingly, AICAR treatment had no corrective effect on 
other mis-spliced genes associated to DM1, like Atp2a1 and Camk2b [85, 217]. Hence, 
it can be hypothesized, that blunted AMPK signalling might secondarily contribute to 
mis-splicing in DM1, but may impact specifically on some affected genes.  
What are the mechanisms underlying AMPK-dependent correction of mis-splicing? 
Considering the mechanism responsible for partial splicing correction in HSALR muscle, 
different options should be considered. First, AICAR itself might interact with the toxic 
mRNA, which may promote the release of RNA-binding proteins, such as MBNL1. 
Alternatively, AICAR and/or AMPK may influence actors that are involved in splicing 
or gene expression regulation. It was previously suggested that AMPK signalling is 
implicated in alternative splicing regulation [139, 232]. Several AMPK activating 
agents, such as berberine, curcumine and resveratrol have been reported to modulate 
splicing events [233-235]. It remains unclear by which mechanisms these compounds 
affect mRNA splicing and only a few splicing modulating factors were shown to be 
directly or indirectly regulated by AMPK [139, 232, 236].  
In a study from Laustriat et al. (2015), AMPK activation was shown to correct 
the alternative splicing of DM1-affected genes in vitro [139]. AICAR-treated human 
DM1 myoblasts displayed restored mis-splicing of several gene transcripts, including 
ATP2A1. Metformin did as well revert splicing alterations of ATP2A1 and corrected 
CLCN1 mis-splicing in DM1 cells [139]. The authors further suggested that the 
beneficial effect of AMPK on mis-splicing was mediated by the RNA-binding protein 
RBM3 [139]. Both AICAR and metformin induced a reduction of RBM3 gene 
expression, and silencing of RBM3 expression entailed changes in alternative splicing of 
several gene transcripts [139]. In our study, we did not detect any changes in the 
transcriptional levels of RBM3 in muscle from AICAR-treated HSALR mice. Hence, 
another mechanism that remains to be elucidated may be responsible for the splicing 
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correction of Clcn1 transcripts triggered by AICAR and/or AMPK activation. Another 
study (PCT publication no.: WO 2011121109 A1) linked the corrective effect on 
splicing of AMPK activators, including metformin, to the modulation of the RNA-
binding protein ELAVL1/HuR. AMPK activators may target importins, which enhance 
ELAVL1 nuclear import, going along with a depletion of ELAVL1 cytosolic levels and 
thereby trigger the restoration or amelioration of mis-splicing of different transcripts. At 
the same time ELAV1 overexpression aggravated DM1-associated splicing defects. 
However, we still need to verify this hypothesis by assessing ELAV1 localization and 
expression in mutant muscle after AICAR treatment. 
Recent analysis of the nuclear foci formed by the aggregation of (CUG)n-
expanded transcripts brought further insight on the mechanism of action of AICAR 
regarding the amelioration of Clcn1 splicing. Indeed, by conducting fluorescence in situ 
hybridization with a fluorescent (CAG)10 DNA probe on muscle sections, we observed a 
drastic decrease in the proportion of nuclei containing foci in mutant muscle from 
AICAR-treated mice, compared to untreated HSALR mice. This suggests that AMPK 
signalling may improve splicing by promoting the dissociation of the nuclear foci 
formed in DM1 muscle. Destabilization of the foci by perturbing RNA-binding proteins, 
such as hnRNP H, which is known to influence foci stability in DM1 and interacts with 
AMPK, may favour the release of MBNL1 and restore splicing [237, 238]. Although it 
is unlikely that AICAR restores MBNL1 distribution, as MBNL1-dependent Camk2b 
and Atp2a1 mis-splicing [96, 137, 217] is not improved in muscle from AICAR-treated 
mutant mice, we will investigate if the levels and subcellular localization of MBNL1 are 
affected upon AICAR treatment. Moreover, as other alternative splicing events are 
likely corrected upon AICAR treatment, further splicing analyses in muscle from 
AICAR-treated mice may unveil potential candidates mediating the effect of AMPK on 
alternative splicing. Lastly, we will need to test another AMPK-activating compound, 
with a different mechanism of action compared to AICAR. This will allow us to judge 
whether the corrected splicing defect of Clcn1 gene and the reduction of myotonia can 
be attributed to the stimulation of AMPK activity or if AICAR itself mediates muscle 
function amelioration. 
AICAR versus metformin action in skeletal muscle 
Regarding the incongruity between the results obtained in metformin- and AICAR- 
treated mice, it has to be mentioned that the mechanism of action of AICAR and 
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metformin is very different. After entering the cell, the adenosine kinase (AK) converts 
AICAR to ZMP (5-aminoimidazole-4-carboxamide-1-D-ribofuranosyl-5'-
monophosphate), which acts as an AMP (adenosine monophosphate) analog, thus 
allosterically activating AMPK [239]. Metformin inhibits mitochondrial complex I, 
resulting in reduced ATP levels and finally in an accumulation of AMP, thereby 
activating AMPK [240]. Furthermore a wide spectrum of mechanistic effects of 
metformin has been recorded and the underlying molecular mechanisms are still 
incompletely understood. Metformin is toxic at high doses, severely impairs skeletal 
muscle oxidative capacity and is known to cause side effects like muscle pain and 
cramps and sometimes weakness in patients [241-244]. Additionally, high 
concentrations of metformin are required to acutely stimulate AMPK signalling in 
rodent muscle tissue, which may explain the absence of beneficial effect of the drug in 
our study [245]. 
The diverging molecular mechanisms of metformin and AICAR might be a 
reason for the differences comparing our results and those of Laustriat et al. (2015) 
[139]. AICAR and metformin action may vary between species and tissues, but these 
compounds could also be more efficient in vitro than in vivo [246]. This might explain 
why AICAR-treated human DM1 myoblasts displayed restored mis-splicing of ATP2A1 
and a down-regulation of RBM3, while we could not detect any of these changes in 
muscle from AICAR-treated HSALR mice [139]. Regarding the results for metformin, we 
assume that its impact was simply not strong enough to have an effect on splicing in 
muscle tissue as the activation state of AMPK and mTORC1 targets was not strongly 
and reproducibly changed in muscle from metformin-treated mice. 
Importantly, the therapeutic potential of metformin is currently being studied in 
a clinical trial with DM1 patients (EudraCT number: 2013-001732-21). In view of our 
results and of its forecited side-effects in muscle, one may hypothesize that metformin 
might not be suitable as a therapeutic option, at least referring to muscle pathology in 
DM1. In contrast, AICAR could be very beneficial regarding muscle function in DM1 
patients but it is also known to have serious side effects triggering injurious health risks, 
such as alteration of heart metabolism and function, thus minimizing the possibility that 
this compound may be applied in clinics [247]. Hence, dissecting the exact mechanism 
of action by which AICAR induces the substantial improvement of muscle function is 
of major importance and might open new avenues for developing pharmacological 
compounds to treat DM1 patients. 
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 4.3.2 Rapamycin and low-protein diet reduce myotonia in HSALR 
mice  
The last-mentioned results suggest a potential implication of AMPK deregulation in 
DM1 muscle dysfunction. However, during the course of the study, we had to consider 
that indirect mTORC1 inhibition by AICAR, mediates the effect of the drug on DM1 
muscle function. Hence, we investigated whether direct modulation of mTORC1 
activity has as well a positive effect in HSALR mice. 
Rapamycin treatment reduces myotonia independently of mTORC1 inhibition and Clcn1 
mis-splicing in HSALR mice 
Rapamycin treatment resulted in a strong inhibition of mTORC1 and significantly 
reduced myotonia in HSALR mice. Of note, rapamycin had no effect on the mis-splicing 
of Clcn1, indicating that reduction of myotonia occurs independently of the restoration 
of ClC-1 activity. Therefore, alternative compensatory effects may contribute to the 
normalization of such pathophysiological defect. We had to consider that rapamycin 
additionally influences intracellular Ca2+ mobilization, and consequently muscle 
contraction and relaxation via its interaction with FKBP12 (FK506 binding protein) and 
the subsequent perturbation of RyR1 activity [175, 197, 248-250]. Therefore, we 
assessed myotonia in mice treated with the ATP-competitive mTOR inhibitor AZD8055 
[251] and showed that, despite the efficient inhibition of mTORC1, the treatment did 
not decrease the late relaxation time of HSALR muscle. Thus, we conclude that the 
reduction of myotonia following rapamycin injections is caused by the drug itself and 
potentially by its effect on FKBP12, rather than due to the modulation of mTORC1 
signalling.  
Protein restriction diminishes myotonia through splicing-independent mechanisms in 
HSALR mice 
We further demonstrate that submitting aging HSALR mice to low-protein diet (LPD) 
induces a significant reduction of DM1-associated myotonia. LPD led to body weight 
loss and corrected myotonia in 10 month-old animals, while it had no effect in young 
mice. It is well-known that protein restriction is more effective in older animals, as 
protein synthesis is blunted in their muscle when the quantity of protein-intake 
undercuts a certain limit, while in young mice a more drastic reduction of proteins is 
required to abate protein synthesis [252-254]. As the above-quoted results most likely 
exclude an involvement of mTORC1 deregulation in triggering myotonia, we suspect 
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that AMPK activation upon LPD may be responsible for the reduced relaxation time of 
mutant muscle. However, in contrast to AICAR, LPD did not correct the mis-regulated 
alternative splicing of Clcn1 in HSALR muscle, indicating that reduction in myotonia 
through protein restriction occurs independently from restoration of ClC-1 activity. One 
can hypothesize that LPD is not sufficient to strongly induce activation of AMPK 
signalling, and the associated changes in Clcn1 alternative splicing. Hence, alternative 
mechanisms may contribute to myotonia reduction upon LPD and may rely on other 
signalling targeted by protein restriction. 
 4.3.3 Alternative splicing-independent mechanisms involved in 
myotonia improvement 
Regarding the effects of AICAR treatment and LPD, we have to consider that additional 
mechanisms apart from the correction of Clcn1 mis-splicing promote the reduction of 
myotonia in HSALR mice. In particular, AMPK is involved in the regulation of various 
ion-channels and can influence the function of muscle-specific ion channels and pumps, 
like the potassium channel Kir2.1, the sodium channel NaV1.4, or the calcium channel 
Orai1 (Calcium Release-Activated Calcium Modulator 1) [255-258]. These components 
are involved in the control of the resting membrane potential, the initiation and 
propagation of the action potential, as well as in membrane repolarization [255-258]. 
Modulation of the channels can thus affect the contraction and the relaxation of muscle 
fibres [255-258]. In accordance, different drugs such as sodium and calcium channel 
blockers exert an anti-myotonic effect in DM1 patients, without altering abnormal 
splicing [131, 132]. Hence, we can hypothesize that AMPK activation may regulate 
muscle relaxation in HSALR mice through its impact on various ion channels in skeletal 
muscle [255-258]. The effect of AMPK on myotonia may also be indirect and related to 
AMPK-dependent regulation of other signalling, such as GSK3β, whose modulation 
was proven to be beneficial for muscle function in HSALR mice [83, 227-229]. However 
the underlying mechanisms linking these signalling pathways to myotonia have, not yet 
been identified. Lastly, one can hypothesize that AMPK activation by AICAR indirectly 
improves muscle function in HSALR mice by modifying the contractile properties of the 
mutant muscle. In particular, reduction in myotonia may be achieved by a fast-to-slow 
fibre type transition, as this might be indicated by the normal relaxation time of soleus 
muscle in HSALR mice. Ljubicic et al. (2011) demonstrated that chronic AICAR-
mediated AMPK activation triggers a fast-to-slow fibre type switch in muscle from mdx 
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mice [259]. It is well known that AMPK signalling stimulates SIRT1 (Sirtuin 1), 
ultimately leading to increased PGC1α (peroxisome proliferator-activated receptor γ 
coactivator 1α) expression, which has been shown to promote the slow myogenic 
program [260, 261]. To test this hypothesis, we recently conducted nicotinamide 
adenine dinucleotide (NADH) staining and immunostaining against the different types 
of myosin in order to identify potential changes in the metabolic and contractile 
properties of treated mutant muscle. However, after 7 days of AICAR treatment as well 
as after 10 days of rapamycin treatment, HSALR muscles did not display modifications of 
their oxidative capacity nor could we detect alterations in the proportion of the different 
fibre types. Similar experiments remain to be conducted for mutant mice submitted to 
LPD, to determine whether this treatment induced changes in the properties of the 
muscle and thus mediated reduction of myotonia.  
 4.3.4 Inhibition of mTORC1 activity partially enhances muscle force 
in HSALR mice 
Concordant with the results obtained with AICAR and rapamycin treatments, we 
observed a significant increase in muscle strength in the animals that received 
AZD8055. Hence, it can be hypothesized that normalization of altered mTORC1 
signalling induces force gain in DM1 muscle. The augmentation in muscle strength after 
AICAR treatment is consistent with the results obtained in a previous study showing 
force gain in mdx mice, following AICAR injections [262]. Decreased muscle 
degeneration, as shown in AICAR-treated mdx mice and in HSALR mice treated with 
different agents modulating GSK3β levels might account for improved muscle strength 
[83, 262]. However, we have to consider that these treatments were applied for 4 and 2 
weeks respectively, whereas the AICAR-treatment we applied lasted only for 7 days. 
Therefore, it is questionable whether in this short time frame muscle regeneration is 
sufficiently advanced, so that it has an impact on muscle strength. mTORC1 may 
alternatively influence muscle force generation by increasing the half-time of Ca2+ 
decay, affecting RyR1 and the synthesis and/or the stability of CaV1.1, further 
influencing the frequency and amount of calcium releasing processes [248, 263, 264]. 
Notably, it has been reported that the expression of the embryonic CaV1.1 isoform, 
causing increased and harmful calcium influx, correlates with the degree of muscle 
weakness in DM1 patients and may contribute to DM1 muscle pathophysiology [104, 
265, 266]. Hence one can speculate that inhibition of mTORC1 may improve muscle 
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function, by triggering a decrease in CaV1.1 protein levels subsequently modulating 
altered Ca2+ homeostasis in HSALR muscle [263].  
In the short term, further investigations will be conducted to judge whether 
AICAR, rapamycin and AZD8055 augment muscle strength by promoting muscle 
regeneration and/or by inducing changes in Ca2+ handling in HSALR muscle. Moreover, 
the treatment duration might not have been long enough to obtain visible results in 
muscle, as we could not observe amelioration in muscle histology. Longer treatment 
periods will also be tested to evaluate the long-term potential of these drugs on DM1 
muscle function. 
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5. Conclusion  
During my PhD, I identified that deregulation of AMPK-mTORC1 signalling, in 
association with an impairment of the autophagic flux, may constitute key pathogenic 
mechanisms in DM1 disease. Autophagy seems to be moderately deregulated, but may 
contribute to muscle alterations in DM1. Approaches targeting AMPK and mTORC1 
signalling considerably improved muscle function in a DM1 mouse model, hence 
underlining the implication of these central metabolic pathways in the disease. Blunted 
AMPK activity may worsen the myotonic phenotype through splicing-dependent and -
independent mechanisms, and deregulated mTORC1 signalling may accentuate muscle 
weakness in DM1. 
This study raises further questions and paves the way for future investigations. 
As skeletal muscle consists of the biggest organ in human it should be considered that 
the identified defective metabolic signalling may influence the whole body homeostasis 
and could greatly affect different organ function. In addition, non-muscle tissues might 
also be affected by similar signalling deregulation in DM1 patients, which may 
contribute to the multisystemic symptoms observed in the disease. Another interesting, 
open question may concern the involvement of mitochondrial defect, and thus energy 
management in DM1 disease, in conjunction with impaired AMPK activity and its 
potential impact on PGC1α [267]. The effect of CaMKII deficiency, beside its potential 
involvement in metabolic signalling imbalance on DM1 muscle, also constitutes an 
interesting research topic. Indeed, with regard to the role of CaMKII in the maintenance 
and the plasticity of NMJs, its deregulation in DM1 muscle might perturb NMJ function 
and thereby may contribute to muscle alterations in the disease [268]. 
In conclusion, the results obtained during my PhD may help to further 
understand the mechanisms underlying the multisystemic DM1 pathology. This work 
illustrates that deregulated cellular processes and signalling pathways are of major 
importance for the DM1-related muscle disease. Hence, we bring new insight to an 
aspect of DM1 pathogenesis, which did not attract too much interest in the past, but may 
account for central disease features, like myotonia and muscle weakness. At the same 
time, this work indicates the participation of novel unknown mechanisms in DM1 
pathology and opens new research prospects. Lastly, we furnish alternative approaches 
in addition to the targeting of toxic transcripts that may provide a basis to develop novel 
therapeutic strategies to treat muscle pathophysiology in DM1 patients.  
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